# Official Journal C 334/30 D

| | ISSN 1725-2423 |
| --- | --- |
| Official Journal
  of the European Union | C 334 |
| | |
| English edition | Information and Notices | Volume 4830 December 2005 |

ISSN 1725-2423

Official Journal

of the European Union

C 334

English edition

Information and Notices

Volume 4830 December 2005

---

| Notice No | Contents | page |
| --- | --- | --- |
| | I   Information |
| | Council |
| 2005/C 334/1 | Convention on the law applicable to contractual obligations (Consolidated version) — First protocol on the interpretation of the 1980 convention by the Court of Justice (Consolidated version) — Second protocol conferring on the Court of Justice powers to interpret the 1980 convention (Consolidated version) | 1 |
| | Commission |
| 2005/C 334/2 | Euro exchange rates | 28 |
| 2005/C 334/3 | Prior notification of a concentration (Case COMP/M.4044 — Tietoenator/Tietoenator Government/SAAB/Elesco/Tietosaab Systems JV) — Candidate case for simplified procedure (
  1
  ) | 29 |
| 2005/C 334/4 | Prior notification of a concentration (Case COMP/M.4074 — Magna/CTS) — Candidate case for simplified procedure (
  1
  ) | 30 |
| 2005/C 334/5 | Prior notification of a concentration (Case COMP/M.4089 — Gilde/Heiploeg) (
  1
  ) | 31 |
| 2005/C 334/6 | Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 November 2005 to 19 November 2005(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93) | 32 |
| 2005/C 334/7 | Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 November 2005 to 19 November 2005(Decisions taken pursuant to Article 34 of Directive 2001/83/EC or Article 38 of Directive 2001/82/EC) | 35 |
| 2005/C 334/8 | Summary of Community decisions on marketing authorizations in respect of medicinal products from 20 November 2005 to 30 November 2005(Decisions taken pursuant to Article 34 of Directive 2001/83/EC or Article 38 of Directive 2001/82/EC) | 38 |
| 2005/C 334/9 | Summary of Community decisions on marketing authorizations in respect of medicinal products from 15 December 2004 to 15 January 2005(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93 | 58 |
| 2005/C 334/0 | Publication of an application for registration pursuant to Article 6(2) of Regulation (EEC) No 2081/92 on the protection of geographical indications and designations of origin | 59 |
| 2005/C 334/1 | Prior notification of a concentration (Case COMP/M.4067 — Blackstone/Lion Capital/CSEB) — Candidate case for simplified procedure (
  1
  ) | 62 |
| | European Defence Agency |
| 2005/C 334/2 | Communication relating to the revision of the financial provisions applicable to the general budget | 63 |

Notice No

Contents

page

I   Information

Council

2005/C 334/1

Convention on the law applicable to contractual obligations (Consolidated version) — First protocol on the interpretation of the 1980 convention by the Court of Justice (Consolidated version) — Second protocol conferring on the Court of Justice powers to interpret the 1980 convention (Consolidated version)

(Consolidated version)

(Consolidated version)

(Consolidated version)

1

Commission

2005/C 334/2

Euro exchange rates

28

2005/C 334/3

Prior notification of a concentration (Case COMP/M.4044 — Tietoenator/Tietoenator Government/SAAB/Elesco/Tietosaab Systems JV) — Candidate case for simplified procedure (
  1
  )

1

29

2005/C 334/4

Prior notification of a concentration (Case COMP/M.4074 — Magna/CTS) — Candidate case for simplified procedure (
  1
  )

1

30

2005/C 334/5

Prior notification of a concentration (Case COMP/M.4089 — Gilde/Heiploeg) (
  1
  )

1

31

2005/C 334/6

Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 November 2005 to 19 November 2005(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93)

(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93)

32

2005/C 334/7

Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 November 2005 to 19 November 2005(Decisions taken pursuant to Article 34 of Directive 2001/83/EC or Article 38 of Directive 2001/82/EC)

(Decisions taken pursuant to Article 34 of Directive 2001/83/EC or Article 38 of Directive 2001/82/EC)

35

2005/C 334/8

Summary of Community decisions on marketing authorizations in respect of medicinal products from 20 November 2005 to 30 November 2005(Decisions taken pursuant to Article 34 of Directive 2001/83/EC or Article 38 of Directive 2001/82/EC)

(Decisions taken pursuant to Article 34 of Directive 2001/83/EC or Article 38 of Directive 2001/82/EC)

38

2005/C 334/9

Summary of Community decisions on marketing authorizations in respect of medicinal products from 15 December 2004 to 15 January 2005(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93

(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93

58

2005/C 334/0

Publication of an application for registration pursuant to Article 6(2) of Regulation (EEC) No 2081/92 on the protection of geographical indications and designations of origin

59

2005/C 334/1

Prior notification of a concentration (Case COMP/M.4067 — Blackstone/Lion Capital/CSEB) — Candidate case for simplified procedure (
  1
  )

1

62

European Defence Agency

2005/C 334/2

Communication relating to the revision of the financial provisions applicable to the general budget

63

---

| | |
| --- | --- |
| | (1)   Text with EEA relevance |

---

(1)   Text with EEA relevance

1

| EN | |
| --- | --- |

EN

---

I Information

Council

| 30.12.2005 | EN | Official Journal of the European Union | C 334/1 |
| --- | --- | --- | --- |

30.12.2005

EN

Official Journal of the European Union

C 334/1

---

CONVENTION ON THE LAW APPLICABLE TO CONTRACTUAL OBLIGATIONS

(Consolidated version)

FIRST PROTOCOL ON THE INTERPRETATION OF THE 1980 CONVENTION BY THE COURT OF JUSTICE

(Consolidated version)

SECOND PROTOCOL CONFERRING ON THE COURT OF JUSTICE POWERS TO INTERPRET THE 1980 CONVENTION

(Consolidated version)

(2005/C 334/01)

PRELIMINARY NOTE

The signing on 14 April 2005 of the Convention on the accession of the Czech Republic, the Republic of Estonia, the Republic of Cyprus, the Republic of Latvia, the Republic of Lithuania, the Republic of Hungary, the Republic of Malta, the Republic of Poland, the Republic of Slovenia and the Slovak Republic to the Rome Convention on the law applicable to contractual obligations and to the two Protocols on its interpretation by the Court of Justice has made it desirable to produce a consolidated version of the Rome Convention and those two Protocols.

These texts are accompanied by six declarations, the first one made in 1980 with regard to the need for consistency between measures to be adopted on choice-of-law rules by the Community and those under the Convention, the second, also made in 1980, on the interpretation of the Convention by the Court of Justice, the third, made in 1996, concerning compliance with the procedure provided for in Article 23 of the Rome Convention as regards carriage of goods by sea, the fourth, made in 2005 concerning the deadlines set for ratification of the Accession Conventions, the fifth, also made in 2005, concerning the timing of the submission of the proposal for a Regulation on the law applicable to contractual obligations, and the sixth, also made in 2005, on the exchange of information.

The text printed in this edition was drawn up by the General Secretariat of the Council, in whose archives the originals of the instruments concerned are deposited. It should be noted, however, that this text has no binding force. The official texts of the instruments consolidated are to be found in the following Official Journals.

| Language version of the Official Journal | 1980 Convention | 1984 Accession Convention | 1988 First Protocol | 1988 Second Protocol | 1992 Accession Convention | 1996 Accession Convention | 2005 Accession Convention |
| --- | --- | --- | --- | --- | --- | --- | --- |
| German | L 266, 9.10.1980, p. 1 | L 146, 31.5.1984, p. 1 | L 48, 20.2.1989, p. 1 | L 48, 20.2.1989, p. 17 | L 333, 18.11.1992, p. 1 | C 15, 15.1.1997, p. 10 | C 169, 8.7.2005, p. 1 |
| English | L 266, 9.10.1980, p. 1 | L 146, 31.5.1984, p. 1 | L 48, 20.2.1989, p. 1 | L 48, 20.2.1989, p. 17 | L 333, 18.11.1992, p. 1 | C 15, 15.1.1997, p. 10 | C 169, 8.7.2005, p. 1 |
| Danish | L 266, 9.10.1980, p. 1 | L 146, 31.5.1984, p. 1 | L 48, 20.2.1989, p. 1 | L 48, 20.2.1989, p. 17 | L 333, 18.11.1992, p. 1 | C 15, 15.1.1997, p. 10 | C 169, 8.7.2005, p. 1 |
| French | L 266, 9.10.1980, p. 1 | L 146, 31.5.1984, p. 1 | L 48, 20.2.1989, p. 1 | L 48, 20.2.1989, p. 17 | L 333, 18.11.1992, p. 1 | C 15, 15.1.1997, p. 10 | C 169, 8.7.2005, p. 1 |
| Greek | L 146, 31.5.1984, p. 7 | L 146, 31.5.1984, p. 1 | L 48, 20.2.1989, p. 1 | L 48, 20.2.1989, p. 17 | L 333, 18.11.1992, p. 1 | C 15, 15.1.1997, p. 10 | C 169, 8.7.2005, p. 1 |
| Irish | Special Edition (L 266) | Special Edition (L 146) | Special Edition (L 48) | Special Edition (L 48) | Special Edition (L 333) | Special Edition (C 15) | Special Edition (C 169) |
| Italian | L 266, 9.10.1980, p. 1 | L 146, 31.5.1984, p. 1 | L 48, 20.2.1989, p. 1 | L 48, 20.2.1989, p. 17 | L 333, 18.11.1992, p. 1 | C 15, 15.1.1997, p. 10 | C 169, 8.7.2005, p. 1 |
| Dutch | L 266, 9.10.1980, p. 1 | L 146, 31.5.1984, p. 1 | L 48, 20.2.1989, p. 1 | L 48, 20.2.1989, p. 17 | L 333, 18.11.1992, p. 1 | C 15, 15.1.1997, p. 10 | C 169, 8.7.2005, p. 1 |
| Spanish | Special Edition,
  Chapter 1, Volume 3, p. 36
  (see also OJ L 333, p. 17) | Special Edition,
  Chapter 1, Volume 4, p. 36
  (see also OJ L 333, p. 72) | L 48, 20.2.1989, p. 1 | L 48, 20.2.1989, p. 17 | L 333, 18.11.1992, p. 1 | C 15, 15.1.1997, p. 10 | C 169, 8.7.2005, p. 1 |
| Portuguese | Special Edition,
  Chapter 1, Volume 3, p. 36
  (see also OJ L 333, p. 7) | Special Edition,
  Chapter 1, Volume 4, p. 72
  (see also OJ L 333, p. 7) | L 48, 20.2.1989, p. 1 | L 48, 20.2.1989, p. 17 | L 333, 18.11.1992, p. 1 | C 15, 15.1.1997, p. 10 | C 169, 8.7.2005, p. 1 |
| Finnish | C 15, 15.1.1997, p. 70 | C 15, 15.1.1997, p. 66 | C 15, 15.1.1997, p. 60 | C 15, 15.1.1997, p. 64 | C 15, 15.1.1997, p. 68 | C 15, 15.1.1997, p. 53 | C 169, 8.7.2005, p. 1 |
| Swedish | C 15, 15.1.1997, p. 70 | C 15, 15.1.1997, p. 66 | C 15, 15.1.1997, p. 60 | C 15, 15.1.1997, p. 64 | C 15, 15.1.1997, p. 68 | C 15, 15.1.1997, p. 53 | C 169, 8.7.2005, p. 1 |
| Czech | C 169, 8.7.2005, p. 10 | C 169, 8.7.2005, p. 23 | C 169, 8.7.2005, p. 10 | C 169, 8.7.2005, p. 10 | C 169, 8.7.2005, p. 26 | C 169, 8.7.2005, p. 28 | C 169, 8.7.2005, p. 1 |
| Estonian | C 169, 8.7.2005, p. 10 | C 169, 8.7.2005, p. 23 | C 169, 8.7.2005, p. 10 | C 169, 8.7.2005, p. 10 | C 169, 8.7.2005, p. 26 | C 169, 8.7.2005, p. 28 | C 169, 8.7.2005, p. 1 |
| Latvian | C 169, 8.7.2005, p. 10 | C 169, 8.7.2005, p. 23 | C 169, 8.7.2005, p. 10 | C 169, 8.7.2005, p. 10 | C 169, 8.7.2005, p. 26 | C 169, 8.7.2005, p. 28 | C 169, 8.7.2005, p. 1 |
| Lithuanian | C 169, 8.7.2005, p. 10 | C 169, 8.7.2005, p. 23 | C 169, 8.7.2005, p. 10 | C 169, 8.7.2005, p. 10 | C 169, 8.7.2005, p. 26 | C 169, 8.7.2005, p. 28 | C 169, 8.7.2005, p. 1 |
| Hungarian | C 169, 8.7.2005, p. 10 | C 169, 8.7.2005, p. 23 | C 169, 8.7.2005, p. 10 | C 169, 8.7.2005, p. 10 | C 169, 8.7.2005, p. 26 | C 169, 8.7.2005, p. 28 | C 169, 8.7.2005, p. 1 |
| Maltese | C 169, 8.7.2005, p. 10 | C 169, 8.7.2005, p. 23 | C 169, 8.7.2005, p. 10 | C 169, 8.7.2005, p. 10 | C 169, 8.7.2005, p. 26 | C 169, 8.7.2005, p. 28 | C 169, 8.7.2005, p. 1 |
| Polish | C 169, 8.7.2005, p. 10 | C 169, 8.7.2005, p. 23 | C 169, 8.7.2005, p. 10 | C 169, 8.7.2005, p. 10 | C 169, 8.7.2005, p. 26 | C 169, 8.7.2005, p. 28 | C 169, 8.7.2005, p. 1 |
| Slovak | C 169, 8.7.2005, p. 10 | C 169, 8.7.2005, p. 23 | C 169, 8.7.2005, p. 10 | C 169, 8.7.2005, p. 10 | C 169, 8.7.2005, p. 26 | C 169, 8.7.2005, p. 28 | C 169, 8.7.2005, p. 1 |
| Slovene | C 169, 8.7.2005, p. 10 | C 169, 8.7.2005, p. 23 | C 169, 8.7.2005, p. 10 | C 169, 8.7.2005, p. 10 | C 169, 8.7.2005, p. 26 | C 169, 8.7.2005, p. 28 | C 169, 8.7.2005, p. 1 |

Language version of the Official Journal

1980 Convention

1984 Accession Convention

1988 First Protocol

1988 Second Protocol

1992 Accession Convention

1996 Accession Convention

2005 Accession Convention

German

L 266, 9.10.1980, p. 1

L 146, 31.5.1984, p. 1

L 48, 20.2.1989, p. 1

L 48, 20.2.1989, p. 17

L 333, 18.11.1992, p. 1

C 15, 15.1.1997, p. 10

C 169, 8.7.2005, p. 1

English

L 266, 9.10.1980, p. 1

L 146, 31.5.1984, p. 1

L 48, 20.2.1989, p. 1

L 48, 20.2.1989, p. 17

L 333, 18.11.1992, p. 1

C 15, 15.1.1997, p. 10

C 169, 8.7.2005, p. 1

Danish

L 266, 9.10.1980, p. 1

L 146, 31.5.1984, p. 1

L 48, 20.2.1989, p. 1

L 48, 20.2.1989, p. 17

L 333, 18.11.1992, p. 1

C 15, 15.1.1997, p. 10

C 169, 8.7.2005, p. 1

French

L 266, 9.10.1980, p. 1

L 146, 31.5.1984, p. 1

L 48, 20.2.1989, p. 1

L 48, 20.2.1989, p. 17

L 333, 18.11.1992, p. 1

C 15, 15.1.1997, p. 10

C 169, 8.7.2005, p. 1

Greek

L 146, 31.5.1984, p. 7

L 146, 31.5.1984, p. 1

L 48, 20.2.1989, p. 1

L 48, 20.2.1989, p. 17

L 333, 18.11.1992, p. 1

C 15, 15.1.1997, p. 10

C 169, 8.7.2005, p. 1

Irish

Special Edition (L 266)

Special Edition (L 146)

Special Edition (L 48)

Special Edition (L 48)

Special Edition (L 333)

Special Edition (C 15)

Special Edition (C 169)

Italian

L 266, 9.10.1980, p. 1

L 146, 31.5.1984, p. 1

L 48, 20.2.1989, p. 1

L 48, 20.2.1989, p. 17

L 333, 18.11.1992, p. 1

C 15, 15.1.1997, p. 10

C 169, 8.7.2005, p. 1

Dutch

L 266, 9.10.1980, p. 1

L 146, 31.5.1984, p. 1

L 48, 20.2.1989, p. 1

L 48, 20.2.1989, p. 17

L 333, 18.11.1992, p. 1

C 15, 15.1.1997, p. 10

C 169, 8.7.2005, p. 1

Spanish

Special Edition,

Chapter 1, Volume 3, p. 36

(see also OJ L 333, p. 17)

Special Edition,

Chapter 1, Volume 4, p. 36

(see also OJ L 333, p. 72)

L 48, 20.2.1989, p. 1

L 48, 20.2.1989, p. 17

L 333, 18.11.1992, p. 1

C 15, 15.1.1997, p. 10

C 169, 8.7.2005, p. 1

Portuguese

Special Edition,

Chapter 1, Volume 3, p. 36

(see also OJ L 333, p. 7)

Special Edition,

Chapter 1, Volume 4, p. 72

(see also OJ L 333, p. 7)

L 48, 20.2.1989, p. 1

L 48, 20.2.1989, p. 17

L 333, 18.11.1992, p. 1

C 15, 15.1.1997, p. 10

C 169, 8.7.2005, p. 1

Finnish

C 15, 15.1.1997, p. 70

C 15, 15.1.1997, p. 66

C 15, 15.1.1997, p. 60

C 15, 15.1.1997, p. 64

C 15, 15.1.1997, p. 68

C 15, 15.1.1997, p. 53

C 169, 8.7.2005, p. 1

Swedish

C 15, 15.1.1997, p. 70

C 15, 15.1.1997, p. 66

C 15, 15.1.1997, p. 60

C 15, 15.1.1997, p. 64

C 15, 15.1.1997, p. 68

C 15, 15.1.1997, p. 53

C 169, 8.7.2005, p. 1

Czech

C 169, 8.7.2005, p. 10

C 169, 8.7.2005, p. 23

C 169, 8.7.2005, p. 10

C 169, 8.7.2005, p. 10

C 169, 8.7.2005, p. 26

C 169, 8.7.2005, p. 28

C 169, 8.7.2005, p. 1

Estonian

C 169, 8.7.2005, p. 10

C 169, 8.7.2005, p. 23

C 169, 8.7.2005, p. 10

C 169, 8.7.2005, p. 10

C 169, 8.7.2005, p. 26

C 169, 8.7.2005, p. 28

C 169, 8.7.2005, p. 1

Latvian

C 169, 8.7.2005, p. 10

C 169, 8.7.2005, p. 23

C 169, 8.7.2005, p. 10

C 169, 8.7.2005, p. 10

C 169, 8.7.2005, p. 26

C 169, 8.7.2005, p. 28

C 169, 8.7.2005, p. 1

Lithuanian

C 169, 8.7.2005, p. 10

C 169, 8.7.2005, p. 23

C 169, 8.7.2005, p. 10

C 169, 8.7.2005, p. 10

C 169, 8.7.2005, p. 26

C 169, 8.7.2005, p. 28

C 169, 8.7.2005, p. 1

Hungarian

C 169, 8.7.2005, p. 10

C 169, 8.7.2005, p. 23

C 169, 8.7.2005, p. 10

C 169, 8.7.2005, p. 10

C 169, 8.7.2005, p. 26

C 169, 8.7.2005, p. 28

C 169, 8.7.2005, p. 1

Maltese

C 169, 8.7.2005, p. 10

C 169, 8.7.2005, p. 23

C 169, 8.7.2005, p. 10

C 169, 8.7.2005, p. 10

C 169, 8.7.2005, p. 26

C 169, 8.7.2005, p. 28

C 169, 8.7.2005, p. 1

Polish

C 169, 8.7.2005, p. 10

C 169, 8.7.2005, p. 23

C 169, 8.7.2005, p. 10

C 169, 8.7.2005, p. 10

C 169, 8.7.2005, p. 26

C 169, 8.7.2005, p. 28

C 169, 8.7.2005, p. 1

Slovak

C 169, 8.7.2005, p. 10

C 169, 8.7.2005, p. 23

C 169, 8.7.2005, p. 10

C 169, 8.7.2005, p. 10

C 169, 8.7.2005, p. 26

C 169, 8.7.2005, p. 28

C 169, 8.7.2005, p. 1

Slovene

C 169, 8.7.2005, p. 10

C 169, 8.7.2005, p. 23

C 169, 8.7.2005, p. 10

C 169, 8.7.2005, p. 10

C 169, 8.7.2005, p. 26

C 169, 8.7.2005, p. 28

C 169, 8.7.2005, p. 1

---

CONVENTION (1) ON THE LAW APPLICABLE TO CONTRACTUAL OBLIGATIONS OPENED FOR SIGNATURE IN ROME ON 19 JUNE 1980

PREAMBLE

THE HIGH CONTRACTING PARTIES to the Treaty establishing the European Economic Community,

ANXIOUS to continue in the field of private international law the work of unification of law which has already been done within the Community, in particular in the field of jurisdiction and enforcement of judgments,

WISHING to establish uniform rules concerning the law applicable to contractual obligations,

HAVE AGREED AS FOLLOWS:

TITLE I

SCOPE OF THE CONVENTION

Article 1

Scope of the Convention

1.   The rules of this Convention shall apply to contractual obligations in any situation involving a choice between the laws of different countries.

2.   They shall not apply to:

| (a) | questions involving the status or legal capacity of natural persons, without prejudice to Article 11; |
| --- | --- |

(a)

questions involving the status or legal capacity of natural persons, without prejudice to Article 11;

| (b) | contractual obligations relating to:






  — | wills and succession, |
| --- | --- | --- |

(b)

contractual obligations relating to:

—

wills and succession,

| — | rights in property arising out of a matrimonial relationship, |
| --- | --- |

—

rights in property arising out of a matrimonial relationship,

| — | rights and duties arising out of a family relationship, parentage, marriage or affinity, including maintenance obligations in respect of children who are not legitimate; |
| --- | --- |

—

rights and duties arising out of a family relationship, parentage, marriage or affinity, including maintenance obligations in respect of children who are not legitimate;

| (c) | obligations arising under bills of exchange, cheques and promissory notes and other negotiable instruments to the extent that the obligations under such other negotiable instruments arise out of their negotiable character; |
| --- | --- |

(c)

obligations arising under bills of exchange, cheques and promissory notes and other negotiable instruments to the extent that the obligations under such other negotiable instruments arise out of their negotiable character;

| (d) | arbitration agreements and agreements on the choice of court; |
| --- | --- |

(d)

arbitration agreements and agreements on the choice of court;

| (e) | questions governed by the law of companies and other bodies corporate or unincorporate such as the creation, by registration or otherwise, legal capacity, internal organisation or winding up of companies and other bodies corporate or unincorporate and the personal liability of officers and members as such for the obligations of the company or body; |
| --- | --- |

(e)

questions governed by the law of companies and other bodies corporate or unincorporate such as the creation, by registration or otherwise, legal capacity, internal organisation or winding up of companies and other bodies corporate or unincorporate and the personal liability of officers and members as such for the obligations of the company or body;

| (f) | the question whether an agent is able to bind a principal, or an organ to bind a company or body corporate or unincorporate, to a third party; |
| --- | --- |

(f)

the question whether an agent is able to bind a principal, or an organ to bind a company or body corporate or unincorporate, to a third party;

| (g) | the constitution of trusts and the relationship between settlors, trustees and beneficiaries; |
| --- | --- |

(g)

the constitution of trusts and the relationship between settlors, trustees and beneficiaries;

| (h) | evidence and procedure, without prejudice to Article 14. |
| --- | --- |

(h)

evidence and procedure, without prejudice to Article 14.

3.   The rules of this Convention do not apply to contracts of insurance which cover risks situated in the territories of the Member States of the European Economic Community. In order to determine whether a risk is situated in those territories the court shall apply its internal law.

4.   The preceding paragraph does not apply to contracts of re-insurance.

Article 2

Application of law of non-contracting States

Any law specified by this Convention shall be applied whether or not it is the law of a Contracting State.

TITLE II

UNIFORM RULES

Article 3

Freedom of choice

1.   A contract shall be governed by the law chosen by the parties. The choice must be expressed or demonstrated with reasonable certainty by the terms of the contract or the circumstances of the case. By their choice the parties can select the law applicable to the whole or a part only of the contract.

2.   The parties may at any time agree to subject the contract to a law other than that which previously governed it, whether as a result of an earlier choice under this Article or of other provisions of this Convention. Any variation by the parties of the law to be applied made after the conclusion of the contract shall not prejudice its formal validity under Article 9 or adversely affect the rights of third parties.

3.   The fact that the parties have chosen a foreign law, whether or not accompanied by the choice of a foreign tribunal, shall not, where all the other elements relevant to the situation at the time of the choice are connected with one country only, prejudice the application of rules of the law at the country which cannot be derogated from by contract, hereinafter called ‘mandatory rules’.

4.   The existence and validity of the consent of the parties as to the choice of the applicable law shall be determined in accordance with the provisions of Articles 8, 9 and 11.

Article 4

Applicable law in the absence of choice

1.   To the extent that the law applicable to the contract has not been chosen in accordance with Article 3, the contract shall be governed by the law of the country with which it is most closely connected. Nevertheless, a separable part of the contract which has a closer connection with another country may by way of exception be governed by the law of that other country.

2.   Subject to the provisions of paragraph 5 of this Article, it shall be presumed that the contract is most closely connected with the country where the party who is to effect the performance which is characteristic of the contract has, at the time of conclusion of the contract, his habitual residence, or, in the case of a body corporate or unincorporate, its central administration. However, if the contract is entered into in the course of that party's trade or profession, that country shall be the country in which the principal place of business is situated or, where under the terms of the contract the performance is to be effected through a place of business other than the principal place of business, the country in which that other place of business is situated.

3.   Notwithstanding the provisions of paragraph 2 of this Article, to the extent that the subject matter of the contract is a right in immovable property or a right to use immovable property it shall be presumed that the contract is most closely connected with the country where the immovable property is situated.

4.   A contract for the carriage of goods shall not be subject to the presumption in paragraph 2. In such a contract if the country in which, at the time the contract is concluded, the carrier has his principal place of business is also the country in which the place of loading or the place of discharge or the principal place of business of the consignor is situated, it shall be presumed that the contract is most closely connected with that country. In applying this paragraph single voyage charter-parties and other contracts the main purpose of which is the carriage of goods shall be treated as contracts for the carriage of goods.

5.   Paragraph 2 shall not apply if the characteristic performance cannot be determined, and the presumptions in paragraphs 2, 3 and 4 shall be disregarded if it appears from the circumstances as a whole that the contract is more closely connected with another country.

Article 5

Certain consumer contracts

1.   This Article applies to a contract the object of which is the supply of goods or services to a person (‘the consumer’) for a purpose which can be regarded as being outside his trade or profession, or a contract for the provision of credit for that object.

2.   Notwithstanding the provisions of Article 3, a choice of law made by the parties shall not have the result of depriving the consumer of the protection afforded to him by the mandatory rules of the law of the country in which he has his habitual residence:

| — | if in that country the conclusion of the contract was preceded by a specific invitation addressed to him or by advertising, and he had taken in that country all the steps necessary on his part for the conclusion of the contract, or |
| --- | --- |

—

if in that country the conclusion of the contract was preceded by a specific invitation addressed to him or by advertising, and he had taken in that country all the steps necessary on his part for the conclusion of the contract, or

| — | if the other party or his agent received the consumer's order in that country, or |
| --- | --- |

—

if the other party or his agent received the consumer's order in that country, or

| — | if the contract is for the sale of goods and the consumer travelled from that country to another country and there gave his order, provided that the consumer's journey was arranged by the seller for the purpose of inducing the consumer to buy. |
| --- | --- |

—

if the contract is for the sale of goods and the consumer travelled from that country to another country and there gave his order, provided that the consumer's journey was arranged by the seller for the purpose of inducing the consumer to buy.

3.   Notwithstanding the provisions of Article 4, a contract to which this Article applies shall, in the absence of choice in accordance with Article 3, be governed by the law of the country in which the consumer has his habitual residence if it is entered into in the circumstances described in paragraph 2 of this Article.

4.   This Article shall not apply to:

| (a) | a contract of carriage; |
| --- | --- |

(a)

a contract of carriage;

| (b) | a contract for the supply of services where the services are to be supplied to the consumer exclusively in a country other than that in which he has his habitual residence. |
| --- | --- |

(b)

a contract for the supply of services where the services are to be supplied to the consumer exclusively in a country other than that in which he has his habitual residence.

5.   Notwithstanding the provisions of paragraph 4, this Article shall apply to a contract which, for an inclusive price, provides for a combination of travel and accommodation.

Article 6

Individual employment contracts

1.   Notwithstanding the provisions of Article 3, in a contract of employment a choice of law made by the parties shall not have the result of depriving the employee of the protection afforded to him by the mandatory rules of the law which would be applicable under paragraph 2 in the absence of choice.

2.   Notwithstanding the provisions of Article 4, a contract of employment shall, in the absence of choice in accordance with Article 3, be governed:

| (a) | by the law of the country in which the employee habitually carries out his work in performance of the contract, even if he is temporarily employed in another country; or |
| --- | --- |

(a)

by the law of the country in which the employee habitually carries out his work in performance of the contract, even if he is temporarily employed in another country; or

| (b) | if the employee does not habitually carry out his work in any one country, by the law of the country in which the place of business through which he was engaged is situated; |
| --- | --- |

(b)

if the employee does not habitually carry out his work in any one country, by the law of the country in which the place of business through which he was engaged is situated;

unless it appears from the circumstances as a whole that the contract is more closely connected with another country, in which case the contract shall be governed by the law of that country.

Article 7

Mandatory rules

1.   When applying under this Convention the law of a country, effect may be given to the mandatory rules of the law of another country with which the situation has a close connection, if and in so far as, under the law of the latter country, those rules must be applied whatever the law applicable to the contract. In considering whether to give effect to these mandatory rules, regard shall be had to their nature and purpose and to the consequences of their application or non-application.

2.   Nothing in this Convention shall restrict the application of the rules of the law of the forum in a situation where they are mandatory irrespective of the law otherwise applicable to the contract.

Article 8

Material validity

1.   The existence and validity of a contract, or of any term of a contract, shall be determined by the law which would govern it under this Convention if the contract or term were valid.

2.   Nevertheless a party may rely upon the law of the country in which he has his habitual residence to establish that he did not consent if it appears from the circumstances that it would not be reasonable to determine the effect of his conduct in accordance with the law specified in the preceding paragraph.

Article 9

Formal validity

1.   A contract concluded between persons who are in the same country is formally valid if it satisfies the formal requirements of the law which governs it under this Convention or of the law of the country where it is concluded.

2.   A contract concluded between persons who are in different countries is formally valid if it satisfies the formal requirements of the law which governs it under this Convention or of the law of one of those countries.

3.   Where a contract is concluded by an agent, the country in which the agent acts is the relevant country for the purposes of paragraphs 1 and 2.

4.   An act intended to have legal effect relating to an existing or contemplated contract is formally valid if it satisfies the formal requirements of the law which under this Convention governs or would govern the contract or of the law of the country where the act was done.

5.   The provisions of the preceding paragraphs shall not apply to a contract to which Article 5 applies, concluded in the circumstances described in paragraph 2 of Article 5. The formal validity of such a contract is governed by the law of the country in which the consumer has his habitual residence.

6.   Notwithstanding paragraphs 1 to 4 of this Article, a contract the subject matter of which is a right in immovable property or a right to use immovable property shall be subject to the mandatory requirements of form of the law of the country where the property is situated if by that law those requirements are imposed irrespective of the country where the contract is concluded and irrespective of the law governing the contract.

Article 10

Scope of applicable law

1.   The law applicable to a contract by virtue of Articles 3 to 6 and 12 of this Convention shall govern in particular:

| (a) | interpretation; |
| --- | --- |

(a)

interpretation;

| (b) | performance; |
| --- | --- |

(b)

performance;

| (c) | within the limits of the powers conferred on the court by its procedural law, the consequences of breach, including the assessment of damages in so far as it is governed by rules of law; |
| --- | --- |

(c)

within the limits of the powers conferred on the court by its procedural law, the consequences of breach, including the assessment of damages in so far as it is governed by rules of law;

| (d) | the various ways of extinguishing obligations, and prescription and limitation of actions; |
| --- | --- |

(d)

the various ways of extinguishing obligations, and prescription and limitation of actions;

| (e) | the consequences of nullity of the contract. |
| --- | --- |

(e)

the consequences of nullity of the contract.

2.   In relation to the manner of performance and the steps to be taken in the event of defective performance regard shall be had to the law of the country in which performance takes place.

Article 11

Incapacity

In a contract concluded between persons who are in the same country, a natural person who would have capacity under the law of that country may invoke his incapacity resulting from another law only if the other party to the contract was aware of this incapacity at the time of the conclusion of the contract or was not aware thereof as a result of negligence.

Article 12

Voluntary assignment

1.   The mutual obligations of assignor and assignee under a voluntary assignment of a right against another person (‘the debtor’) shall be governed by the law which under this Convention applies to the contract between the assignor and assignee.

2.   The law governing the right to which the assignment relates shall determine its assignability, the relationship between the assignee and the debtor, the conditions under which the assignment can be invoked against the debtor and any question whether the debtor's obligations have been discharged.

Article 13

Subrogation

1.   Where a person (‘the creditor’) has a contractual claim upon another (‘the debtor’), and a third person has a duty to satisfy the creditor, or has in fact satisfied the creditor in discharge of that duty, the law which governs the third person's duty to satisfy the creditor shall determine whether the third person is entitled to exercise against the debtor the rights which the creditor had against the debtor under the law governing their relationship and, if so, whether he may do so in full or only to a limited extent.

2.   The same rule applies where several persons are subject to the same contractual claim and one of them has satisfied the creditor.

Article 14

Burden of proof, etc.

1.   The law governing the contract under this Convention applies to the extent that it contains, in the law of contract, rules which raise presumptions of law or determine the burden of proof.

2.   A contract or an act intended to have legal effect may be proved by any mode of proof recognised by the law of the forum or by any of the laws referred to in Article 9 under which that contract or act is formally valid, provided that such mode of proof can be administered by the forum.

Article 15

Exclusion of convoi

The application of the law of any country specified by this Convention means the application of the rules of law in force in that country other than its rules of private international law.

Article 16

‘Ordre public’

The application of a rule of the law of any country specified by this Convention may be refused only if such application is manifestly incompatible with the public policy (‘ordre public’) of the forum.

Article 17

No retrospective effect

This Convention shall apply in a Contracting State to contracts made after the date on which this Convention has entered into force with respect to that State.

Article 18

Uniform interpretation

In the interpretation and application of the preceding uniform rules, regard shall be had to their international character and to the desirability of achieving uniformity in their interpretation and application.

Article 19

States with more than one legal system

1.   Where a State comprises several territorial units each of which has its own rules of law in respect of contractual obligations, each territorial unit shall be considered as a country for the purposes of identifying the law applicable under this Convention.

2.   A State within which different territorial units have their own rules of law in respect of contractual obligations shall not be bound to apply this Convention to conflicts solely between the laws of such units.

Article 20

Precedence of Community law

This Convention shall not affect the application of provisions which, in relation to particular matters, lay down choice of law rules relating to contractual obligations and which are or will be contained in acts of the institutions of the European Communities or in national laws harmonised in implementation of such acts.

Article 21

Relationship with other conventions

This Convention shall not prejudice the application of international conventions to which a Contracting State is, or becomes, a party.

Article 22

Reservations

1.   Any Contracting State may, at the time of signature, ratification, acceptance or approval, reserve the right not to apply:

| (a) | the provisions of Article 7(1); |
| --- | --- |

(a)

the provisions of Article 7(1);

| (b) | the provisions of Article 10(1) (e). |
| --- | --- |

(b)

the provisions of Article 10(1) (e).

3.   Any Contracting State may at any time withdraw a reservation which it has made; the reservation shall cease to have effect on the first day of the third calendar month after notification of the withdrawal.

TITLE III

FINAL PROVISIONS

Article 23

1.   If, after the date on which this Convention has entered into force for a Contracting State, that State wishes to adopt any new choice of law rule in regard to any particular category of contract within the scope of this Convention, it shall communicate its intention to the other signatory States through the Secretary-General of the Council of the European Communities.

2.   Any signatory State may, within six months from the date of the communication made to the Secretary-General, request him to arrange consultations between signatory States in order to reach agreement. (...) (3).

3.   If no signatory State has requested consultations within this period or if within two years following the communication made to the Secretary-General no agreement is reached in the course of consultations, the Contracting State concerned may amend its law in the manner indicated. The measures taken by that State shall be brought to the knowledge of the other signatory States through the Secretary-General of the Council of the European Communities.

Article 24

1.   If, after the date on which this Convention has entered into force with respect to a Contracting State, that State wishes to become a party to a multilateral convention whose principal aim or one of whose principal aims is to lay down rules of private international law concerning any of the matters governed by this Convention, the procedure set out in Article 23 shall apply. However, the period of two years, referred to in paragraph 3 of that Article, shall be reduced to one year.

2.   The procedure referred to in the preceding paragraph need not be followed if a Contracting State or one of the European Communities is already a party to the multilateral convention, or if its object is to revise a convention to which the State concerned is already a party, or if it is a convention concluded within the framework of the Treaties establishing the European Communities.

Article 25

If a Contracting State considers that the unification achieved by this Convention is prejudiced by the conclusion of agreements not covered by Article 24(1), that State may request the Secretary-General of the Council of the European Communities to arrange consultations between the signatory States of this Convention.

Article 26

Any Contracting State may request the revision of this Convention. In this event a revision conference shall be convened by the President of the Council of the European Communities.

Article 27 (4)

Article 28

1.   This Convention shall be open from 19 June 1980 for signature by the States party to the Treaty establishing the European Economic Community.

2.   This Convention shall be subject to ratification, acceptance or approval by the signatory States. The instruments of ratification, acceptance or approval shall be deposited with the Secretary-General of the Council of the European Communities (5).

Article 29 (6)

1.   This Convention shall enter into force on the first day of the third month following the deposit of the seventh instrument of ratification, acceptance or approval.

2.   This Convention shall enter into force for each signatory State ratifying, accepting or approving at a later date on the first day of the third month following the deposit of its instrument of ratification, acceptance or approval.

Article 30

1.   This Convention shall remain in force for 10 years from the date of its entry into force in accordance with Article 29(1), even for States for which it enters into force at a later date.

2.   If there has been no denunciation it shall be renewed tacitly every five years.

3.   A Contracting State which wishes to denounce shall, not less than six months before the expiration of the period of 10 or five years, as the case may be, give notice to the Secretary-General of the Council of the European Communities. (7).

4.   The denunciation shall have effect only in relation to the State which has notified it. The Convention will remain in force as between all other Contracting States.

Article 31 (8)

The Secretary-General of the Council of the European Communities shall notify the States party to the Treaty establishing the European Economic Community of:

| (a) | the signatures; |
| --- | --- |

(a)

the signatures;

| (b) | deposit of each instrument of ratification, acceptance or approval; |
| --- | --- |

(b)

deposit of each instrument of ratification, acceptance or approval;

| (c) | the date of entry into force of this Convention; |
| --- | --- |

(c)

the date of entry into force of this Convention;

| (d) | communications made in pursuance of Articles 23, 24, 25, 26 and 30 (9); |
| --- | --- |

(d)

communications made in pursuance of Articles 23, 24, 25, 26 and 30 (9);

| (e) | the reservations and withdrawals of reservations referred to in Article 22. |
| --- | --- |

(e)

the reservations and withdrawals of reservations referred to in Article 22.

Article 32

The Protocol annexed to this Convention shall form an integral part thereof.

Article 33 (10)

This Convention, drawn up in a single original in the Danish, Dutch, English, French, German, Irish and Italian languages, these texts being equally authentic, shall be deposited in the archives of the Secretariat of the Council of the European Communities. The Secretary-General shall transmit a certified copy thereof to the Government of each signatory State.

In witness whereof the undersigned, being duly authorised thereto, having signed this Convention.

Done at Rome on the nineteenth day of June in the year one thousand nine hundred and eighty.

[Signatures of the plenipotentiaries]

---

(1)  Text as amended by the Convention of 10 April 1984 on the accession of the Hellenic Republic – hereafter referred to as the ‘1984 Accession Convention’ –, by the Convention of 18 May 1992 on the accession of the Kingdom of Spain and the Portuguese Republic – hereafter referred to as the ‘1992 Accession Convention’ –, by the Convention of 29 November 1996 on the accession of the Republic of Austria, the Republic of Finland and the Kingdom of Sweden – hereafter referred to as the ‘1996 Accession Convention’ – and by the Convention of 14 April 2005 on the accession of the Czech Republic, the Republic of Estonia, the Republic of Cyprus, the Republic of Latvia, the Republic of Lithuania, the Republic of Hungary, the Republic of Malta, the Republic of Poland, the Republic of Slovenia and the Slovak Republic – hereafter referred to as the ‘2005 Accession Convention.’

1

(2)  Paragraph deleted by Article 2(1) of the 1992 Accession Convention.

2

(3)  Phrase deleted by the 1992 Accession Convention.

3

(4)  Article deleted by Article 2(1) of the 1992 Accession Convention.

4

(5)  Ratification of the Accession Conventions is governed by the following provisions of those Conventions:

5

| — | as regards the 1984 Accession Convention, by Article 3 of that Convention, which reads as follows:

  ‘Article 3
  This Convention shall be ratified by signatory States. The instruments of ratification shall be deposited with the Secretary-General of the Council of the European Communities.’, |
| --- | --- |

—

as regards the 1984 Accession Convention, by Article 3 of that Convention, which reads as follows:

‘Article 3

This Convention shall be ratified by signatory States. The instruments of ratification shall be deposited with the Secretary-General of the Council of the European Communities.’,

| — | as regards the 1992 Accession Convention, by Article 4 of that Convention, which reads as follows:

  ‘Article 4
  This Convention shall be ratified by signatory States. The instruments of ratification shall be deposited with the Secretary-General of the Council of the European Communities.’, |
| --- | --- |

—

as regards the 1992 Accession Convention, by Article 4 of that Convention, which reads as follows:

‘Article 4

This Convention shall be ratified by signatory States. The instruments of ratification shall be deposited with the Secretary-General of the Council of the European Communities.’,

| — | as regards the 1996 Accession Convention, by Article 5 of that Convention, which reads as follows:

  ‘Article 5
  This Convention shall be ratified by signatory States. The instruments of ratification shall be deposited with the Secretary-General of the Council of the European Union.’, |
| --- | --- |

—

as regards the 1996 Accession Convention, by Article 5 of that Convention, which reads as follows:

‘Article 5

This Convention shall be ratified by signatory States. The instruments of ratification shall be deposited with the Secretary-General of the Council of the European Union.’,

| — | as regards the 2005 Accession Convention, by Article 4 of the Convention, which reads as follows:

  ‘Article 4
  This Convention shall be ratified by signatory States. The instruments of ratification shall be deposited with the Secretary-General of the Council of the European Union.’. |
| --- | --- |

—

as regards the 2005 Accession Convention, by Article 4 of the Convention, which reads as follows:

‘Article 4

This Convention shall be ratified by signatory States. The instruments of ratification shall be deposited with the Secretary-General of the Council of the European Union.’.

(6)  The entry into force of the Accession Conventions is governed by the following provisions of those Conventions:

6

| — | as regards the 1984 Accession Convention, by Article 4 of that Convention, which reads as follows:

  ‘Article 4
  This Convention shall enter into force, as between the States which have ratified it, on the first day of the third month following the deposit of the last instrument of ratification by the Hellenic Republic and seven States which have ratified the Convention on the law applicable to contractual obligations.
  This Convention shall enter into force for each Contracting State which subsequently ratifies it on the first day of the third month following the deposit of its instrument of ratification.’, |
| --- | --- |

—

as regards the 1984 Accession Convention, by Article 4 of that Convention, which reads as follows:

‘Article 4

This Convention shall enter into force, as between the States which have ratified it, on the first day of the third month following the deposit of the last instrument of ratification by the Hellenic Republic and seven States which have ratified the Convention on the law applicable to contractual obligations.

This Convention shall enter into force for each Contracting State which subsequently ratifies it on the first day of the third month following the deposit of its instrument of ratification.’,

| — | as regards the 1992 Accession Convention, by Article 5 of that Convention, which reads as follows:

  ‘Article 5
  This Convention shall enter into force, as between the States which have ratified it, on the first day of the third month following the deposit of the last instrument of ratification by the Kingdom of Spain or the Portuguese Republic and by one State which has ratified the Convention on the law applicable to contractual obligations.
  This Convention shall enter into force for each Contracting State which subsequently ratifies it on the first day of the third month following the deposit of its instrument of ratification.’, |
| --- | --- |

—

as regards the 1992 Accession Convention, by Article 5 of that Convention, which reads as follows:

‘Article 5

This Convention shall enter into force, as between the States which have ratified it, on the first day of the third month following the deposit of the last instrument of ratification by the Kingdom of Spain or the Portuguese Republic and by one State which has ratified the Convention on the law applicable to contractual obligations.

This Convention shall enter into force for each Contracting State which subsequently ratifies it on the first day of the third month following the deposit of its instrument of ratification.’,

| — | as regards the 1996 Accession Convention, by Article 6 of that Convention, which reads as follows:

  ‘Article 6
  1.   This Convention shall enter into force, as between the States which have ratified it, on the first day of the third month following the deposit of the last instrument of ratification by the Republic of Austria, the Republic of Finland or the Kingdom of Sweden and by one Contracting State which has ratified the Convention on the law applicable to contractual obligations.
  2.   This Convention shall enter into force for each Contracting State which subsequently ratifies it on the first day of the third month following the deposit of its instrument of ratification.’, |
| --- | --- |

—

as regards the 1996 Accession Convention, by Article 6 of that Convention, which reads as follows:

‘Article 6

1.   This Convention shall enter into force, as between the States which have ratified it, on the first day of the third month following the deposit of the last instrument of ratification by the Republic of Austria, the Republic of Finland or the Kingdom of Sweden and by one Contracting State which has ratified the Convention on the law applicable to contractual obligations.

2.   This Convention shall enter into force for each Contracting State which subsequently ratifies it on the first day of the third month following the deposit of its instrument of ratification.’,

| — | as regards the 2005 Accession Convention, by Article 5 of the Convention, which reads as follows:

  ‘Article 5
  1.   This Convention shall enter into force between the States which have ratified it, on the first day of the third month following the deposit of the second instrument of ratification.’
  2.   Thereafter, this Convention shall enter into force, for each signatory State which subsequently ratifies it, on the first day of the third month following the deposit of its instrument of ratification. |
| --- | --- |

—

as regards the 2005 Accession Convention, by Article 5 of the Convention, which reads as follows:

‘Article 5

1.   This Convention shall enter into force between the States which have ratified it, on the first day of the third month following the deposit of the second instrument of ratification.’

2.   Thereafter, this Convention shall enter into force, for each signatory State which subsequently ratifies it, on the first day of the third month following the deposit of its instrument of ratification.

(7)  Phrase deleted by the 1992 Accession Convention.

7

(8)  Notification concerning the Accession Conventions is governed by the following provisions of those Conventions:

8

| — | as regards the 1984 Accession Convention, by Article 5 of that Convention, which reads as follows:

  ‘Article 5
  The Secretary-General of the Council of the European Communities shall notify the signatory States of:






  (a) | the deposit of each instrument of ratification; |
| --- | --- | --- |

—

as regards the 1984 Accession Convention, by Article 5 of that Convention, which reads as follows:

‘Article 5

The Secretary-General of the Council of the European Communities shall notify the signatory States of:

(a)

the deposit of each instrument of ratification;

| (b) | the dates of entry into force of this Convention for the Contracting States.’, |
| --- | --- |

(b)

the dates of entry into force of this Convention for the Contracting States.’,

| — | as regards the 1992 Accession Convention, by Article 6 of that Convention, which reads as follows:

  ‘Article 6
  The Secretary-General of the Council of the European Communities shall notify the signatory States of:






  (a) | the deposit of each instrument of ratification; |
| --- | --- | --- |

—

as regards the 1992 Accession Convention, by Article 6 of that Convention, which reads as follows:

‘Article 6

The Secretary-General of the Council of the European Communities shall notify the signatory States of:

(a)

the deposit of each instrument of ratification;

| (b) | the dates of entry into force of this Convention for the Contracting States.’, |
| --- | --- |

(b)

the dates of entry into force of this Convention for the Contracting States.’,

| — | as regards the 1996 Accession Convention, by Article 7 of that Convention, which reads as follows:

  ‘Article 7
  The Secretary-General of the Council of the European Union shall notify the signatory States of:






  (a) | the deposit of each instrument of ratification; |
| --- | --- | --- |

—

as regards the 1996 Accession Convention, by Article 7 of that Convention, which reads as follows:

‘Article 7

The Secretary-General of the Council of the European Union shall notify the signatory States of:

(a)

the deposit of each instrument of ratification;

| (b) | the dates of entry into force of this Convention for the Contracting States.’, |
| --- | --- |

(b)

the dates of entry into force of this Convention for the Contracting States.’,

| — | as regards the 2005 Accession Convention, by Article 6 of the Convention, which reads as follows:

  ‘Article 6
  The Secretary-General of the Council of the European Communities shall notify the signatory States of:






  (a) | the deposit of each instrument of ratification; |
| --- | --- | --- |

—

as regards the 2005 Accession Convention, by Article 6 of the Convention, which reads as follows:

‘Article 6

The Secretary-General of the Council of the European Communities shall notify the signatory States of:

(a)

the deposit of each instrument of ratification;

| (b) | the dates of entry into force of this Convention for the Contracting States.’ |
| --- | --- |

(b)

the dates of entry into force of this Convention for the Contracting States.’

(9)  Point (d) as amended by the 1992 Accession Convention.

9

(10)  An indication of the authentic texts of the Accession Convention is to be found in the following provisions:

10

| — | as regards the 1984 Accession Convention, in Articles 2 and 6 of that Convention, which reads as follows:

  ‘Article 2
  The Secretary-General of the Council of the European Communities shall transmit a certified copy of the Convention on the law applicable to contractual obligations in the Danish, Dutch, English, French, German, Irish and Italian languages to the Government of the Hellenic Republic.
  The text of the Convention on the law applicable to contractual obligations in the Greek language is annexed hereto. The text in the Greek language shall be authentic under the same conditions as the other texts of the Convention on the law applicable to contractual obligations.’


  ‘Article 6
  This Convention, drawn up in a single original in the Danish, Dutch, English, French, German, Greek, Irish and Italian languages, all eight texts being equally authentic, shall be deposited in the archives of the General Secretariat of the Council of the European Communities. The Secretary-General shall transmit a certified copy to the government of each Signatory State.’ |
| --- | --- |

—

as regards the 1984 Accession Convention, in Articles 2 and 6 of that Convention, which reads as follows:

‘Article 2

The Secretary-General of the Council of the European Communities shall transmit a certified copy of the Convention on the law applicable to contractual obligations in the Danish, Dutch, English, French, German, Irish and Italian languages to the Government of the Hellenic Republic.

The text of the Convention on the law applicable to contractual obligations in the Greek language is annexed hereto. The text in the Greek language shall be authentic under the same conditions as the other texts of the Convention on the law applicable to contractual obligations.’

‘Article 6

This Convention, drawn up in a single original in the Danish, Dutch, English, French, German, Greek, Irish and Italian languages, all eight texts being equally authentic, shall be deposited in the archives of the General Secretariat of the Council of the European Communities. The Secretary-General shall transmit a certified copy to the government of each Signatory State.’

| — | as regards the 1992 Accession Convention, in Articles 3 and 7 of that Convention, which reads as follows:

  ‘Article 3
  1.   The Secretary-General of the Council of the European Communities shall transmit a certified copy of the Convention on the law applicable to contractual obligations in the Danish, Dutch, English, French, German, Greek, Irish and Italian languages to the Governments of the Kingdom of Spain and the Portuguese Republic.
  2.   The text of the Convention on the law applicable to contractual obligations in the Portuguese and Spanish languages is set out in Annexes I and II to this Convention. The texts drawn up in the Portuguese and Spanish languages shall be authentic under the same conditions as the other texts of the Convention on the law applicable to contractual obligations.’


  ‘Article 7
  This Convention, drawn up in a single original in the Danish, Dutch, English, French, German, Greek, Irish, Italian, Portuguese and Spanish languages, all ten texts being equally authentic, shall be deposited in the archives of the General Secretariat of the Council of the European Communities. The Secretary-General shall transmit a certified copy to the government of each Signatory State.’ |
| --- | --- |

—

as regards the 1992 Accession Convention, in Articles 3 and 7 of that Convention, which reads as follows:

‘Article 3

1.   The Secretary-General of the Council of the European Communities shall transmit a certified copy of the Convention on the law applicable to contractual obligations in the Danish, Dutch, English, French, German, Greek, Irish and Italian languages to the Governments of the Kingdom of Spain and the Portuguese Republic.

2.   The text of the Convention on the law applicable to contractual obligations in the Portuguese and Spanish languages is set out in Annexes I and II to this Convention. The texts drawn up in the Portuguese and Spanish languages shall be authentic under the same conditions as the other texts of the Convention on the law applicable to contractual obligations.’

‘Article 7

This Convention, drawn up in a single original in the Danish, Dutch, English, French, German, Greek, Irish, Italian, Portuguese and Spanish languages, all ten texts being equally authentic, shall be deposited in the archives of the General Secretariat of the Council of the European Communities. The Secretary-General shall transmit a certified copy to the government of each Signatory State.’

| — | as regards the 1996 Accession Convention, in Articles 4 and 8 of that Convention, which read as follows:

  ‘Article 4
  1.   The Secretary-General of the Council of the European Union shall transmit a certified copy of the Convention of 1980, the Convention of 1984, the First Protocol of 1988, the Second Protocol of 1988 and the Convention of 1992 in the Danish, Dutch, English, French, German, Greek, Irish, Italian, Spanish and Portuguese languages to the Governments of the Republic of Austria, the Republic of Finland and the Kingdom of Sweden.
  2.   The text of the Convention of 1980, the Convention of 1984, the First Protocol of 1988, the Second Protocol of 1988 and the Convention of 1992 in the Finnish and Swedish languages shall be authentic under the same conditions as the other texts of the Convention of 1980, the Convention of 1984, the First Protocol of 1988, the Second Protocol of 1988 and the Convention of 1992.’


  ‘Article 8
  This Convention, drawn up in a single original in the Danish, Dutch, English, Finnish, French, German, Greek, Irish, Italian, Portuguese, Spanish and Swedish languages, all twelve texts being equally authentic, shall be deposited in the archives of the General Secretariat of the Council of the European Union. The Secretary-General shall transmit a certified copy to the government of each Signatory State.’ |
| --- | --- |

—

as regards the 1996 Accession Convention, in Articles 4 and 8 of that Convention, which read as follows:

‘Article 4

1.   The Secretary-General of the Council of the European Union shall transmit a certified copy of the Convention of 1980, the Convention of 1984, the First Protocol of 1988, the Second Protocol of 1988 and the Convention of 1992 in the Danish, Dutch, English, French, German, Greek, Irish, Italian, Spanish and Portuguese languages to the Governments of the Republic of Austria, the Republic of Finland and the Kingdom of Sweden.

2.   The text of the Convention of 1980, the Convention of 1984, the First Protocol of 1988, the Second Protocol of 1988 and the Convention of 1992 in the Finnish and Swedish languages shall be authentic under the same conditions as the other texts of the Convention of 1980, the Convention of 1984, the First Protocol of 1988, the Second Protocol of 1988 and the Convention of 1992.’

‘Article 8

This Convention, drawn up in a single original in the Danish, Dutch, English, Finnish, French, German, Greek, Irish, Italian, Portuguese, Spanish and Swedish languages, all twelve texts being equally authentic, shall be deposited in the archives of the General Secretariat of the Council of the European Union. The Secretary-General shall transmit a certified copy to the government of each Signatory State.’

| — | as regards the 2005 Accession Convention, in Articles 3 and 7 of that Convention, which reads as follows:

  ‘Article 3
  1.   The Secretary-General of the Council of the European Union shall transmit a certified copy of the Convention of 1980, the Convention of 1984, the FirstProtocol of 1988, the Second Protocol of 1988, the Convention of 1992 and the Convention of 1996 in the Danish, Dutch, English, Finnish, French, German, Greek, Irish, Italian, Portuguese, Spanish and Swedish languages to the Governments of the Czech Republic, the Republic of Estonia, the Republic of Cyprus, the Republic of Latvia, the Republic of Lithuania, the Republic of Hungary, the Republic of Malta, the Republic of Poland, the Republic of Slovenia and the Slovak Republic.
  2.   The text of the Convention of 1980, the Convention of 1984, the First Protocol of 1988, the Second Protocol of 1988, the Convention of 1992 and the Convention of 1996 in the Czech, Estonian, Hungarian, Latvian, Lithuanian, Maltese, Polish, Slovakian and Slovenian languages shall be authentic under the same conditions as the other texts of the Convention of 1980, the Convention of 1984, the First Protocol of 1988, the Second Protocol of 1988, the Convention of 1992 and the Convention of 1996.’


  ‘Article
  This Convention, drawn up in a single original in the Czech, Danish, Dutch, English, Estonian, Finnish, French, German, Greek, Hungarian, Irish, Italian, Latvian, Lithuanian, Maltese, Polish, Portuguese, Slovakian, Slovenian, Spanish and Swedish languages, all twenty-one texts being equally authentic, shall be deposited in the archives of the General Secretariat of the Council of the European Union. The Secretary-General shall transmit a certified copy to the Government of each signatory state.’ |
| --- | --- |

—

as regards the 2005 Accession Convention, in Articles 3 and 7 of that Convention, which reads as follows:

‘Article 3

1.   The Secretary-General of the Council of the European Union shall transmit a certified copy of the Convention of 1980, the Convention of 1984, the FirstProtocol of 1988, the Second Protocol of 1988, the Convention of 1992 and the Convention of 1996 in the Danish, Dutch, English, Finnish, French, German, Greek, Irish, Italian, Portuguese, Spanish and Swedish languages to the Governments of the Czech Republic, the Republic of Estonia, the Republic of Cyprus, the Republic of Latvia, the Republic of Lithuania, the Republic of Hungary, the Republic of Malta, the Republic of Poland, the Republic of Slovenia and the Slovak Republic.

2.   The text of the Convention of 1980, the Convention of 1984, the First Protocol of 1988, the Second Protocol of 1988, the Convention of 1992 and the Convention of 1996 in the Czech, Estonian, Hungarian, Latvian, Lithuanian, Maltese, Polish, Slovakian and Slovenian languages shall be authentic under the same conditions as the other texts of the Convention of 1980, the Convention of 1984, the First Protocol of 1988, the Second Protocol of 1988, the Convention of 1992 and the Convention of 1996.’

‘Article

This Convention, drawn up in a single original in the Czech, Danish, Dutch, English, Estonian, Finnish, French, German, Greek, Hungarian, Irish, Italian, Latvian, Lithuanian, Maltese, Polish, Portuguese, Slovakian, Slovenian, Spanish and Swedish languages, all twenty-one texts being equally authentic, shall be deposited in the archives of the General Secretariat of the Council of the European Union. The Secretary-General shall transmit a certified copy to the Government of each signatory state.’

---

PROTOCOL (1)

The High Contracting Parties have agreed upon the following provision which shall be annexed to the Convention:

‘Notwithstanding the provisions of the Convention, Denmark, Sweden and Finland may retain national provisions concerning the law applicable to questions relating to the carriage of goods by sea and may amend such provisions without following the procedure provided for in Article 23 of the Convention of Rome. The national provisions applicable in this respect are the following:

| — | in Denmark, paragraphs 252 and 321 (3) and (4) of the “Sølov” (maritime law), |
| --- | --- |

—

in Denmark, paragraphs 252 and 321 (3) and (4) of the “Sølov” (maritime law),

| — | in Sweden, Chapter 13, Article 2(1) and (2), and Chapter 14, Article 1(3), of “sjölagen” (maritime law), |
| --- | --- |

—

in Sweden, Chapter 13, Article 2(1) and (2), and Chapter 14, Article 1(3), of “sjölagen” (maritime law),

| — | in Finland, Chapter 13, Article 2(1) and (2), and Chapter 14, Article 1(3), of “merilaki”/“sjölagen” (maritime law).’ |
| --- | --- |

—

in Finland, Chapter 13, Article 2(1) and (2), and Chapter 14, Article 1(3), of “merilaki”/“sjölagen” (maritime law).’

In witness whereof the undersigned, being duly authorised thereto, have signed this Protocol.

Done at Rome on the nineteenth day of June in the year one thousand nine hundred and eighty.

[Signatures of the Plenipotentiaries]

---

(1)  Text as amended by the 1996 Accession Convention.

1

---

JOINT DECLARATION

At the time of the signature of the Convention on the law applicable to contractual obligations, the Governments of the Kingdom of Belgium, the Kingdom of Denmark, the Federal Republic of Germany, the French Republic, Ireland, the Italian Republic, the Grand Duchy of Luxembourg, the Kingdom of the Netherlands and the United Kingdom of Great Britain and Northern Ireland,

| I. | anxious to avoid, as far as possible, dispersion of choice of law rules among several instruments and differences between these rules, express the wish that the institutions of the European Communities, in the exercise of their powers under the Treaties by which they were established, will, where the need arises, endeavour to adopt choice of law rules which are as far as possible consistent with those of this Convention; |
| --- | --- |

I.

anxious to avoid, as far as possible, dispersion of choice of law rules among several instruments and differences between these rules, express the wish that the institutions of the European Communities, in the exercise of their powers under the Treaties by which they were established, will, where the need arises, endeavour to adopt choice of law rules which are as far as possible consistent with those of this Convention;

| II. | declare their intention as from the date of signature of this Convention until becoming bound by Article 24, to consult with each other if any one of the signatory States wishes to become a party to any convention to which the procedure referred to in Article 24 would apply; |
| --- | --- |

II.

declare their intention as from the date of signature of this Convention until becoming bound by Article 24, to consult with each other if any one of the signatory States wishes to become a party to any convention to which the procedure referred to in Article 24 would apply;

| III. | having regard to the contribution of the Convention on the law applicable to contractual obligations to the unification of choice of law rules within the European Communities, express the view that any State which becomes a member of the European Communities should accede to this Convention. |
| --- | --- |

III.

having regard to the contribution of the Convention on the law applicable to contractual obligations to the unification of choice of law rules within the European Communities, express the view that any State which becomes a member of the European Communities should accede to this Convention.

In witness whereof the undersigned, being duly authorised thereto, have signed this Joint Declaration.

Done at Rome on the nineteenth day of June in the year one thousand nine hundred and eighty.

[Signatures of the Plenipotentiaries]

---

JOINT DECLARATION

The Governments of the Kingdom of Belgium, the Kingdom of Denmark, the Federal Republic of Germany, the French Republic, Ireland, the Italian Republic, the Grand Duchy of Luxembourg, the Kingdom of the Netherlands and the United Kingdom of Great Britain and Northern Ireland,

On signing the Convention on the law applicable to contractual obligations;

Desiring to ensure that the Convention is applied as effectively as possible;

Anxious to prevent differences of interpretation of the Convention from impairing its unifying effect;

Declare themselves ready:

| 1. | to examine the possibility of conferring jurisdiction in certain matters on the Court of Justice of the European Communities and, if necessary, to negotiate an agreement to this effect; |
| --- | --- |

1.

to examine the possibility of conferring jurisdiction in certain matters on the Court of Justice of the European Communities and, if necessary, to negotiate an agreement to this effect;

| 2. | to arrange meetings at regular intervals between their representatives. |
| --- | --- |

2.

to arrange meetings at regular intervals between their representatives.

In witness whereof the undersigned, being duly authorised thereto, have signed this Joint Declaration.

Done at Rome on the nineteenth day of June in the year one thousand nine hundred and eighty.

[Signatures of the Plenipotentiaries]

---

Joint declaration by the High Contracting Parties concerning the deadlines set for ratification of the Accession Convention

‘The High Contracting Parties, meeting in the Council at the time of the signature of the Convention on the accession of the Czech Republic, the Republic of Estonia, the Republic of Cyprus, the Republic of Latvia, the Republic of Lithuania, the Republic of Hungary, the Republic of Malta, the Republic of Poland, the Republic of Slovenia and the Slovak Republic to the 1980 Rome Convention on the law applicable to contractual obligations, declare that they will take the necessary steps to ratify this Convention within a reasonable time and, if possible, before December 2005.’

---

Declaration by the Member States concerning the timing of the submission of a proposal for a Regulation on the law applicable to contractual obligations

‘The Member States request that the Commission submit, as soon as possible and at the latest by the end of 2005, a proposal for a Regulation on the law applicable to contractual obligations.’

---

Joint Declaration by the Member States on the exchange of information

‘The Governments of the Kingdom of Belgium, the Czech Republic, the Kingdom of Denmark, the Federal Republic of Germany, the Republic of Estonia, the Hellenic Republic, the Kingdom of Spain, the French Republic, Ireland, the Italian Republic, the Republic of Cyprus, the Republic of Latvia, the Republic of Lithuania, the Grand Duchy of Luxembourg, the Republic of Hungary, the Republic of Malta, the Kingdom of the Netherlands, the Republic of Austria, the Republic of Poland, the Portuguese Republic, the Republic of Slovenia, the Slovak Republic, the Republic of Finland, the Kingdom of Sweden and the United Kingdom of Great Britain and Northern Ireland,

On signing the 2005 Convention on accession to the Convention on the law applicable to contractual obligations, opened for signature in Rome on 19 June 1980, and to the First and Second Protocols on interpretation by the Court of Justice of the European Communities, as amended,

Desiring to ensure that the provisions of the First Protocol are applied as effectively and as uniformly as possible,

Declare themselves ready to organise, in cooperation with the Court of Justice of the European Communities, an exchange of information on judgments which have become res judicata and have been handed down pursuant to the Convention on the law applicable to contractual obligations by the courts referred to in Article 2 of the said Protocol. The exchange of information will comprise:

| — | the forwarding to the Court of Justice by the competent national authorities of judgments handed down by the courts referred to in Article 2(a) of the First Protocol and significant judgments handed down by the courts referred to in Article 2(b) of that Protocol, |
| --- | --- |

—

the forwarding to the Court of Justice by the competent national authorities of judgments handed down by the courts referred to in Article 2(a) of the First Protocol and significant judgments handed down by the courts referred to in Article 2(b) of that Protocol,

| — | the classification and the documentary exploitation of these judgments by the Court of Justice including, as far as necessary, the drawing up of abstracts and translations, and the publication of judgments of particular importance, |
| --- | --- |

—

the classification and the documentary exploitation of these judgments by the Court of Justice including, as far as necessary, the drawing up of abstracts and translations, and the publication of judgments of particular importance,

| — | the communication by the Court of Justice of the documentary material to the competent national authorities of the States parties to the Protocol and to the Commission and the Council of the European Communities.’ |
| --- | --- |

—

the communication by the Court of Justice of the documentary material to the competent national authorities of the States parties to the Protocol and to the Commission and the Council of the European Communities.’

---

FIRST PROTOCOL (1) ON THE INTERPRETATION BY THE COURT OF JUSTICE OF THE EUROPEAN COMMUNITIES OF THE CONVENTION ON THE LAW APPLICABLE TO CONTRACTUAL OBLIGATIONS, OPENED FOR SIGNATURE IN ROME ON 19 JUNE 1980

THE HIGH CONTRACTING PARTIES TO THE TREATY ESTABLISHING THE EUROPEAN ECONOMIC COMMUNITY,

HAVING REGARD to the Joint Declaration annexed to the Convention on the law applicable to contractual obligations, opened for signature in Rome on 19 June 1980,

HAVE DECIDED to conclude a Protocol conferring jurisdiction on the Court of Justice of the European Communities to interpret that Convention, and to this end have designated as their Plenipotentiaries:

[Plenipotentiaries designated by the Member States]

WHO, meeting within the Council of the European Communities, having exchanged their full powers, found in good and due form,

HAVE AGREED AS FOLLOWS:

Article 1

The Court of Justice of the European Communities shall have jurisdiction to give rulings on the interpretation of:

| (a) | the Convention on the law applicable to contractual obligations, opened for signature in Rome on 19 June 1980, hereinafter referred to as ‘the Rome Convention’; |
| --- | --- |

(a)

the Convention on the law applicable to contractual obligations, opened for signature in Rome on 19 June 1980, hereinafter referred to as ‘the Rome Convention’;

| (b) | the Convention on accession to the Rome Convention by the States which have become Members of the European Communities since the date on which it was opened for signature; |
| --- | --- |

(b)

the Convention on accession to the Rome Convention by the States which have become Members of the European Communities since the date on which it was opened for signature;

| (c) | this Protocol. |
| --- | --- |

(c)

this Protocol.

Article 2

Any of the courts referred to below may request the Court of Justice to give a preliminary ruling on a question raised in a case pending before it and concerning interpretation of the provisions contained in the instruments referred to in Article 1 if that court considers that a decision on the question is necessary to enable it to give judgment:

| (a) | — | in Belgium:
  ‘la Cour de cassation’ (‘het Hof van Cassatie’) and ‘le Conseil d'État’ (‘de Raad van State’), |
| --- | --- | --- |

(a)

—

in Belgium:

‘la Cour de cassation’ (‘het Hof van Cassatie’) and ‘le Conseil d'État’ (‘de Raad van State’),

| — | in the Czech Republic:
  ‘Nejvyšší soud České republiky’ and ‘Nejvyšší správní soud’, |
| --- | --- |

—

in the Czech Republic:

‘Nejvyšší soud České republiky’ and ‘Nejvyšší správní soud’,

| — | in Denmark:
  ‘Højesteret’, |
| --- | --- |

—

in Denmark:

‘Højesteret’,

| — | in the Federal Republic of Germany:
  ‘die obersten Gerichtshöfe des Bundes’, |
| --- | --- |

—

in the Federal Republic of Germany:

‘die obersten Gerichtshöfe des Bundes’,

| — | in Estonia:
  ‘Riigikohus’, |
| --- | --- |

—

in Estonia:

‘Riigikohus’,

| — | in Greece:
  Τα ανώτατα Δικαστήρια, |
| --- | --- |

—

in Greece:

Τα ανώτατα Δικαστήρια,

| — | in Spain:
  ‘el Tribunal Supremo’, |
| --- | --- |

—

in Spain:

‘el Tribunal Supremo’,

| — | in France:
  ‘la Cour de cassation’ and ‘le Conseil d'État’, |
| --- | --- |

—

in France:

‘la Cour de cassation’ and ‘le Conseil d'État’,

| — | in Ireland:
  the Supreme Court, |
| --- | --- |

—

in Ireland:

the Supreme Court,

| — | in Italy:
  ‘la Corte suprema di cassazione’ and ‘il Consiglio di Stato’, |
| --- | --- |

—

in Italy:

‘la Corte suprema di cassazione’ and ‘il Consiglio di Stato’,

| — | in Cyprus:
  ‘Ανώτατο Δικαστήριο’, |
| --- | --- |

—

in Cyprus:

‘Ανώτατο Δικαστήριο’,

| — | in Latvia:
  ‘Augstākās Tiesas Senāts’, |
| --- | --- |

—

in Latvia:

‘Augstākās Tiesas Senāts’,

| — | in Lithuania:
  ‘Lietuvos Aukščiausiasis Teismas’ and ‘Lietuvos vyriausiasis administracinis teismas’, |
| --- | --- |

—

in Lithuania:

‘Lietuvos Aukščiausiasis Teismas’ and ‘Lietuvos vyriausiasis administracinis teismas’,

| — | in Luxembourg:
  ‘la Cour Supérieure de Justice’ when sitting as ‘Cour de cassation’, |
| --- | --- |

—

in Luxembourg:

‘la Cour Supérieure de Justice’ when sitting as ‘Cour de cassation’,

| — | in Hungary:
  ‘Legfelsõbb Bíróság’, |
| --- | --- |

—

in Hungary:

‘Legfelsõbb Bíróság’,

| — | in Malta:
  ‘Qorti ta' l-Appell’, |
| --- | --- |

—

in Malta:

‘Qorti ta' l-Appell’,

| — | in the Netherlands:
  ‘de Hoge Raad’, |
| --- | --- |

—

in the Netherlands:

‘de Hoge Raad’,

| — | in Austria:
  the ‘Oberste Gerichtshof’, the ‘Verwaltungsgerichtshof’ and the ‘Verfassungsgerichtshof’, |
| --- | --- |

—

in Austria:

the ‘Oberste Gerichtshof’, the ‘Verwaltungsgerichtshof’ and the ‘Verfassungsgerichtshof’,

| — | in Poland:
  ‘Sąd Najwyższy’ and ‘Naczelny Sąd Administracyjny’, |
| --- | --- |

—

in Poland:

‘Sąd Najwyższy’ and ‘Naczelny Sąd Administracyjny’,

| — | in Portugal:
  ‘o Supremo Tribunal de Justiça’ and ‘o Supremo Tribunal Administrativo’, |
| --- | --- |

—

in Portugal:

‘o Supremo Tribunal de Justiça’ and ‘o Supremo Tribunal Administrativo’,

| — | in Slovenia:
  ‘Ustavno sodišče Republike Slovenije’,
  ‘Vrhovno sodišče Republike Slovenije’, |
| --- | --- |

—

in Slovenia:

‘Ustavno sodišče Republike Slovenije’,

‘Vrhovno sodišče Republike Slovenije’,

| — | in Slovakia:
  ‘Najvyšší súd Slovenskej republiky’, |
| --- | --- |

—

in Slovakia:

‘Najvyšší súd Slovenskej republiky’,

| — | in Finland:
  ‘korkein oikeus/högsta domstolen’, ‘korkein hallinto-oikeus/högsta förvaltningsdomstolen’, ‘markkinatuomioistuin/marknadsdomstolen’ and ‘työtuomioistuin/arbetsdomstolen’, |
| --- | --- |

—

in Finland:

‘korkein oikeus/högsta domstolen’, ‘korkein hallinto-oikeus/högsta förvaltningsdomstolen’, ‘markkinatuomioistuin/marknadsdomstolen’ and ‘työtuomioistuin/arbetsdomstolen’,

| — | in Sweden:
  ‘Högsta domstolen’, ‘Regeringsrätten’, ‘Arbetsdomstolen’ and ‘Marknadsdomstolen’, |
| --- | --- |

—

in Sweden:

‘Högsta domstolen’, ‘Regeringsrätten’, ‘Arbetsdomstolen’ and ‘Marknadsdomstolen’,

| — | in the United Kingdom:
  the House of Lords and other courts from which no further appeal is possible; |
| --- | --- |

—

in the United Kingdom:

the House of Lords and other courts from which no further appeal is possible;

| (b) | the courts of the Contracting States when acting as appeal courts. |
| --- | --- |

(b)

the courts of the Contracting States when acting as appeal courts.

Article 3

1.   The competent authority of a Contracting State may request the Court of Justice to give a ruling on a question of interpretation of the provisions contained in the instruments referred to in Article 1 if judgments given by courts of that State conflict with the interpretation given either by the Court of Justice or in a judgment of one of the courts of another Contracting State referred to in Article 2. The provisions of this paragraph shall apply only to judgments which have become res judicata.

2.   The interpretation given by the Court of Justice in response to such a request shall not affect the judgments which gave rise to the request for interpretation.

3.   The Procurators-General of the Supreme Courts of Appeal of the Contracting States, or any other authority designated by a Contracting State, shall be entitled to request the Court of Justice for a ruling on interpretation in accordance with paragraph 1.

4.   The Registrar of the Court of Justice shall give notice of the request to the Contracting States, to the Commission and to the Council of the European Communities; they shall then be entitled within two months of the notification to submit statements of case or written observations to the Court.

5.   No fees shall be levied or any costs or expenses awarded in respect of the proceedings provided for in this Article.

Article 4

1.   Except where this Protocol otherwise provides, the provisions of the Treaty establishing the European Economic Community and those of the Protocol on the Statute of the Court of Justice annexed thereto, which are applicable when the Court is requested to give a preliminary ruling, shall also apply to any proceedings for the interpretation of the instruments referred to in Article 1.

2.   The Rules of Procedure of the Court of Justice shall, if necessary, be adjusted and supplemented in accordance with Article 188 of the Treaty establishing the European Economic Community.

Article 5 (2)

This Protocol shall be subject to ratification by the Signatory States. The instruments of ratification shall be deposited with the Secretary-General of the Council of the European Communities.

Article 6 (3)

1.   To enter into force, this Protocol must be ratified by seven States in respect of which the Rome Convention is in force. This Protocol shall enter into force on the first day of the third month following the deposit of the instrument of ratification by the last such State to take this step. If, however, the Second Protocol conferring on the Court of Justice of the European Communities certain powers to interpret the Convention on the law applicable to contractual obligations, opened for signature in Rome on 19 June 1980, concluded in Brussels on 19 December 1988 (4) enters into force on a later date, this Protocol shall enter into force on the date of entry into force of the Second Protocol.

2.   Any ratification subsequent to the entry into force of this Protocol shall take effect on the first day of the third month following the deposit of the instrument of ratification, provided that the ratification, acceptance or approval of the Rome Convention by the State in question has become effective.

Article 7 (5)

The Secretary-General of the Council of the European Communities shall notify the Signatory States of:

| (a) | the deposit of each instrument of ratification; |
| --- | --- |

(a)

the deposit of each instrument of ratification;

| (b) | the date of entry into force of this Protocol; |
| --- | --- |

(b)

the date of entry into force of this Protocol;

| (c) | any designation communicated pursuant to Article 3(3); |
| --- | --- |

(c)

any designation communicated pursuant to Article 3(3);

| (d) | any communication made pursuant to Article 8. |
| --- | --- |

(d)

any communication made pursuant to Article 8.

Article 8

The Contracting States shall communicate to the Secretary-General of the Council of the European Communities the texts of any provisions of their laws which necessitate an amendment to the list of courts in Article 2(a).

Article 9

This Protocol shall have effect for as long as the Rome Convention remains in force under the conditions laid down in Article 30 of that Convention.

Article 10

Any Contracting State may request the revision of this Protocol. In this event, a revision conference shall be convened by the President of the Council of the European Communities.

Article 11 (6)

This Protocol, drawn up in a single original in the Danish, Dutch, English, French, German, Greek, Irish, Italian, Portuguese and Spanish languages, all 10 texts being equally authentic, shall be deposited in the archives of the General Secretariat of the Council of the European Communities. The Secretary-General shall transmit a certified copy to the Government of each Signatory State.

In witness whereof, the undersigned Plenipotentiaries have affixed their signatures below this Protocol.

Done at Brussels on the nineteenth day of December in the year one thousand nine hundred and eighty-eight.

[Signatures of the Plenipotentiaries]

---

(1)  Text as amended by the 2005 Accession Convention.

1

(2)  See footnote 1 on page 12.

2

(3)  See footnote 3 on page 12.

3

(4)  See page 14.

4

(5)  See footnote 1 on page 13.

5

(6)  See footnote 1 on page 14.

6

---

JOINT DECLARATIONS

Joint Declaration

The Governments of the Kingdom of Belgium, the Kingdom of Denmark, the Federal Republic of Germany, the Hellenic Republic, the Kingdom of Spain, the French Republic, Ireland, the Italian Republic, the Grand Duchy of Luxembourg, the Kingdom of the Netherlands, the Portuguese Republic and the United Kingdom of Great Britain and Northern Ireland,

On signing the First Protocol on the interpretation by the Court of Justice of the European Communities of the Convention on the law applicable to contractual obligations, opened for signature in Rome on 19 June 1980,

Desiring to ensure that the Convention is applied as effectively and as uniformly as possible,

Declare themselves ready to organise, in cooperation with the Court of Justice of the European Communities, an exchange of information on judgments which have become res judicata and have been handed down pursuant to the Convention on the law applicable to contractual obligations by the courts referred to in Article 2 of the said Protocol. The exchange of information will comprise:

| — | the forwarding to the Court of Justice by the competent national authorities of judgments handed down by the courts referred to in Article 2(a) and significant judgments handed down by the courts referred to in Article 2(b), |
| --- | --- |

—

the forwarding to the Court of Justice by the competent national authorities of judgments handed down by the courts referred to in Article 2(a) and significant judgments handed down by the courts referred to in Article 2(b),

| — | the classification and the documentary exploitation of these judgments by the Court of Justice including, as far as necessary, the drawing up of abstracts and translations, and the publication of judgments of particular importance, |
| --- | --- |

—

the classification and the documentary exploitation of these judgments by the Court of Justice including, as far as necessary, the drawing up of abstracts and translations, and the publication of judgments of particular importance,

| — | the communication by the Court of Justice of the documentary material to the competent national authorities of the States parties to the Protocol and to the Commission and the Council of the European Communities. |
| --- | --- |

—

the communication by the Court of Justice of the documentary material to the competent national authorities of the States parties to the Protocol and to the Commission and the Council of the European Communities.

In witness whereof, the undersigned Plenipotentiaries have affixed their signature below this Joint Declaration.

Done at Brussels on the nineteenth day of December in the year one thousand nine hundred and eighty-eight.

[Signatures of the Plenipotentiaries]

Joint Declaration

The Governments of the Kingdom of Belgium, the Kingdom of Denmark, the Federal Republic of Germany, the Hellenic Republic, the Kingdom of Spain, the French Republic, Ireland, the Italian Republic, the Grand Duchy of Luxembourg, the Kingdom of the Netherlands, the Portuguese Republic and the United Kingdom of Great Britain and Northern Ireland,

On signing the First Protocol on the interpretation by the Court of Justice of the European Communities of the Convention on the law applicable to contractual obligations, opened for signature in Rome on 19 June 1980,

Having regard to the Joint Declaration annexed to the Convention on the law applicable to contractual obligations,

Desiring to ensure that the Convention is applied as effectively and as uniformly as possible,

Anxious to prevent differences of interpretation of the Convention from impairing its unifying effect,

Express the view that any State which becomes a member of the European Communities should accede to this Protocol.

In witness whereof, the undersigned Plenipotentiaries have affixed their signatures below this Joint Declaration.

Done at Brussels on the nineteenth day of December in the year one thousand nine hundred and eighty-eight.

[Signatures of the Plenipotentiaries]

---

---

SECOND PROTOCOL CONFERRING ON THE COURT OF JUSTICE OF THE EUROPEAN COMMUNITIES CERTAIN POWERS TO INTERPRET THE CONVENTION ON THE LAW APPLICABLE TO CONTRACTUAL OBLIGATIONS; OPENED FOR SIGNATURE IN ROME ON 19 JUNE 1980

THE HIGH CONTRACTING PARTIES TO THE TREATY ESTABLISHING THE EUROPEAN ECONOMIC COMMUNITY,

WHEREAS the Convention on the law applicable to contractual obligations, opened for signature in Rome on 19 June 1980, hereinafter referred to as ‘the Rome Convention’, will enter into force after the deposit of the seventh instrument of ratification, acceptance or approval;

WHEREAS the uniform application of the rules laid down in the Rome Convention requires that machinery to ensure uniform interpretation be set up and whereas to that end appropriate powers should be conferred upon the Court of Justice of the European Communities, even before the Rome Convention enters into force with respect to all the Member States of the European Economic Community,

HAVE DECIDED to conclude this Protocol and to this end have designated as their Plenipotentiaries:

[Plenipotentiaries designated by the Member States]

WHO, meeting within the Council of the European Communities, having exchanged their full powers; found in good and due form,

HAVE AGREED AS FOLLOWS:

Article 1

1.   The Court of Justice of the European Communities shall, with respect to the Rome Convention, have the jurisdiction conferred upon it by the First Protocol on the interpretation by the Court of Justice of the European Communities of the Convention on the law applicable to contractual obligations, opened for signature in Rome on 19 June 1980, concluded in Brussels on 19 December 1988 (1). The Protocol on the Statute of the Court of Justice of the European Communities and the Rules of Procedure of the Court of Justice shall apply.

2.   The Rules of Procedure of the Court of Justice shall be adapted and supplemented as necessary in accordance with Article 188 of the Treaty establishing the European Economic Community.

Article 2 (2)

This Protocol shall be subject to ratification by the Signatory States. The instruments of ratification shall be deposited with the Secretary-General of the Council of the European Communities.

Article 3 (3)

This Protocol shall enter into force on the first day of the third month following the deposit of the instrument of ratification of the last Signatory State to complete that formality.

Article 4 (4)

This Protocol, drawn up in a single original in the Danish, Dutch, English, French, German, Greek, Irish, Italian, Portuguese and Spanish languages, all 10 texts being equally authentic, shall be deposited in the archives of the General Secretariat of the Council of the European Communities. The Secretary-General shall transmit a certified copy to the Government of each signatory.

In witness whereof, the undersigned Plenipotentiaries have affixed their signature below this Protocol.

Done at Brussels on the nineteenth day of December in the year one thousand nine hundred and eighty-eight.

[Signatures of the Plenipotentiaries]

---

(1)  See page 1.

1

(2)  See footnote 1 on page 12.

2

(3)  See footnote 3 on page 12.

3

(4)  See footnote 1 on page 14.

4

---

Commission

| 30.12.2005 | EN | Official Journal of the European Union | C 334/28 |
| --- | --- | --- | --- |

30.12.2005

EN

Official Journal of the European Union

C 334/28

---

Euro exchange rates (1)

29 December 2005

(2005/C 334/02)

1 euro
  =

| | Currency | Exchange rate |
| --- | --- | --- |
| USD | US dollar | 1,1825 |
| JPY | Japanese yen | 139,43 |
| DKK | Danish krone | 7,4587 |
| GBP | Pound sterling | 0,68830 |
| SEK | Swedish krona | 9,4104 |
| CHF | Swiss franc | 1,5585 |
| ISK | Iceland króna | 75,34 |
| NOK | Norwegian krone | 8,0165 |
| BGN | Bulgarian lev | 1,9558 |
| CYP | Cyprus pound | 0,5735 |
| CZK | Czech koruna | 29,010 |
| EEK | Estonian kroon | 15,6466 |
| HUF | Hungarian forint | 252,51 |
| LTL | Lithuanian litas | 3,4528 |
| LVL | Latvian lats | 0,6966 |
| MTL | Maltese lira | 0,4293 |
| PLN | Polish zloty | 3,8602 |
| RON | Romanian leu | 3,6915 |
| SIT | Slovenian tolar | 239,51 |
| SKK | Slovak koruna | 37,870 |
| TRY | Turkish lira | 1,5963 |
| AUD | Australian dollar | 1,6197 |
| CAD | Canadian dollar | 1,3796 |
| HKD | Hong Kong dollar | 9,1681 |
| NZD | New Zealand dollar | 1,7348 |
| SGD | Singapore dollar | 1,9685 |
| KRW | South Korean won | 1 194,92 |
| ZAR | South African rand | 7,4997 |
| CNY | Chinese yuan renminbi | 9,5438 |
| HRK | Croatian kuna | 7,3750 |
| IDR | Indonesian rupiah | 11 629,89 |
| MYR | Malaysian ringgit | 4,470 |
| PHP | Philippine peso | 62,690 |
| RUB | Russian rouble | 34,0560 |
| THB | Thai baht | 48,431 |

Currency

Exchange rate

USD

US dollar

1,1825

JPY

Japanese yen

139,43

DKK

Danish krone

7,4587

GBP

Pound sterling

0,68830

SEK

Swedish krona

9,4104

CHF

Swiss franc

1,5585

ISK

Iceland króna

75,34

NOK

Norwegian krone

8,0165

BGN

Bulgarian lev

1,9558

CYP

Cyprus pound

0,5735

CZK

Czech koruna

29,010

EEK

Estonian kroon

15,6466

HUF

Hungarian forint

252,51

LTL

Lithuanian litas

3,4528

LVL

Latvian lats

0,6966

MTL

Maltese lira

0,4293

PLN

Polish zloty

3,8602

RON

Romanian leu

3,6915

SIT

Slovenian tolar

239,51

SKK

Slovak koruna

37,870

TRY

Turkish lira

1,5963

AUD

Australian dollar

1,6197

CAD

Canadian dollar

1,3796

HKD

Hong Kong dollar

9,1681

NZD

New Zealand dollar

1,7348

SGD

Singapore dollar

1,9685

KRW

South Korean won

1 194,92

ZAR

South African rand

7,4997

CNY

Chinese yuan renminbi

9,5438

HRK

Croatian kuna

7,3750

IDR

Indonesian rupiah

11 629,89

MYR

Malaysian ringgit

4,470

PHP

Philippine peso

62,690

RUB

Russian rouble

34,0560

THB

Thai baht

48,431

---

(1)

Source: reference exchange rate published by the ECB.

---

| 30.12.2005 | EN | Official Journal of the European Union | C 334/29 |
| --- | --- | --- | --- |

30.12.2005

EN

Official Journal of the European Union

C 334/29

---

Prior notification of a concentration

(Case COMP/M.4044 — Tietoenator/Tietoenator Government/SAAB/Elesco/Tietosaab Systems JV)

Candidate case for simplified procedure

(2005/C 334/03)

(Text with EEA relevance)

| 1. | On 20 December 2005, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertakings SAAB AB (Sweden) including its subsidiary Elesco Oy (Finland) and TietoEnator Corporation including its subsidiary TietoEnator Government Oy (‘TietoEnator’, Finland) acquire within the meaning of Article 3(1)(b) of the Council Regulation joint control of Tietosaab Systems JV (‘TSS’), a newly created company constituting a joint venture through the purchase of shares. |
| --- | --- |

1.

On 20 December 2005, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertakings SAAB AB (Sweden) including its subsidiary Elesco Oy (Finland) and TietoEnator Corporation including its subsidiary TietoEnator Government Oy (‘TietoEnator’, Finland) acquire within the meaning of Article 3(1)(b) of the Council Regulation joint control of Tietosaab Systems JV (‘TSS’), a newly created company constituting a joint venture through the purchase of shares.

| 2. | The business activities of the undertakings concerned are:






  — | for SAAB: Defence company active through Elesco in Command Control and Information system (C2i) and underwater warfare; |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for SAAB: Defence company active through Elesco in Command Control and Information system (C2i) and underwater warfare;

| — | for TietoEnator: information technology systems; |
| --- | --- |

—

for TietoEnator: information technology systems;

| — | for TSS: Command and Control information systems (C2i) and underwater warfare. |
| --- | --- |

—

for TSS: Command and Control information systems (C2i) and underwater warfare.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (No (32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4044 — Tietoenator/Tietoenator Government/SAAB/Elesco/Tietosaab Systems JV, to the following address:





  European Commission |
| --- | --- |
| Competition DG |
| Merger Registry |
| J-70 |
| B-1049 Brussels |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (No (32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4044 — Tietoenator/Tietoenator Government/SAAB/Elesco/Tietosaab Systems JV, to the following address:

European Commission

Competition DG

Merger Registry

J-70

B-1049 Brussels

---

(1)  OJ L 24, 29.1.2004, p. 1.

(2)  OJ C 56, 5.3.2005, p. 32.

---

| 30.12.2005 | EN | Official Journal of the European Union | C 334/30 |
| --- | --- | --- | --- |

30.12.2005

EN

Official Journal of the European Union

C 334/30

---

Prior notification of a concentration

(Case COMP/M.4074 — Magna/CTS)

Candidate case for simplified procedure

(2005/C 334/04)

(Text with EEA relevance)

| 1. | On 19 December 2005, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Magna International Inc. (‘Magna’; Canada) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the undertaking CTS Fahrzeug-Dachsysteme GmbH (‘CTS’; Germany) by way of purchase of shares. |
| --- | --- |

1.

On 19 December 2005, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Magna International Inc. (‘Magna’; Canada) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the undertaking CTS Fahrzeug-Dachsysteme GmbH (‘CTS’; Germany) by way of purchase of shares.

| 2. | The business activities of the undertakings concerned are:






  — | for Magna: diversified global automotive supplier; |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for Magna: diversified global automotive supplier;

| — | for CTS: designs and manufctures convertible roof systems for the automotive industry. |
| --- | --- |

—

for CTS: designs and manufctures convertible roof systems for the automotive industry.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (No (32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4074 — Magna/CTS, to the following address:





  European Commission |
| --- | --- |
| Competition DG |
| Merger Registry |
| J-70 |
| B-1049 Brussels |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (No (32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4074 — Magna/CTS, to the following address:

European Commission

Competition DG

Merger Registry

J-70

B-1049 Brussels

---

(1)  OJ L 24, 29.1.2004, p. 1.

(2)  OJ C 56, 5.3.2005, p. 32.

---

| 30.12.2005 | EN | Official Journal of the European Union | C 334/31 |
| --- | --- | --- | --- |

30.12.2005

EN

Official Journal of the European Union

C 334/31

---

Prior notification of a concentration

(Case COMP/M.4089 — Gilde/Heiploeg)

(2005/C 334/05)

(Text with EEA relevance)

| 1. | On 22 December 2005, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Gilde Buy-out Management Holding B.V. (‘Gilde’, the Netherlands) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the undertaking Heiploeg Beheer B.V. (‘Heiploeg’, the Netherlands) by way of purchase of shares. |
| --- | --- |

1.

On 22 December 2005, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Gilde Buy-out Management Holding B.V. (‘Gilde’, the Netherlands) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the undertaking Heiploeg Beheer B.V. (‘Heiploeg’, the Netherlands) by way of purchase of shares.

| 2. | The business activities of the undertakings concerned are:






  — | for Gilde: a private equity investor specialized in management buy-out investments; |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for Gilde: a private equity investor specialized in management buy-out investments;

| — | for Heiploeg: sourcing, processing, distributing and selling of shrimps. |
| --- | --- |

—

for Heiploeg: sourcing, processing, distributing and selling of shrimps.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (No (32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4089 — Gilde/Heiploeg, to the following address:





  European Commission |
| --- | --- |
| Competition DG |
| Merger Registry |
| J-70 |
| B-1049 Brussels |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (No (32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4089 — Gilde/Heiploeg, to the following address:

European Commission

Competition DG

Merger Registry

J-70

B-1049 Brussels

---

(1)  OJ L 24, 29.1.2004, p. 1.

---

| 30.12.2005 | EN | Official Journal of the European Union | C 334/32 |
| --- | --- | --- | --- |

30.12.2005

EN

Official Journal of the European Union

C 334/32

---

Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 November 2005 to 19 November 2005

(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93 (1))

(2005/C 334/06)

—   Modification of a marketing authorization (Article 12 of Council Regulation (EEC) No 2309/93): Accepted

| Date of the decision | Name of the medicinal product | Holder of the marketing authorization | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 7.11.2005 | Abilify | Otsuka Pharmaceutical Europe Ltd, Commonwealth House, 2 Chalkhill Road, Hammersmith, London W6 8DW, United Kingdom | EU/1/04/276/001-032 | 9.11.2005 |
| 7.11.2005 | Kivexa | Glaxo Group Ltd, Berkeley Avenue, Greenford, Middlesex UB6 0NN, United Kingdom | EU/1/04/298/001-002 | 9.11.2005 |
| 7.11.2005 | Ziagen | Glaxo Group Ltd, Greenford, Middlesex UB6 0NN, United Kingdom | EU/1/99/112/001-002 | 9.11.2005 |
| 7.11.2005 | Rapamune | Wyeth Europa Limited, Huntercombe Lane South, Taplow, Maidenhead, Berkshire, SL6 0PH, United Kingdom | EU/1/01/171/001-012 | 9.11.2005 |
| 7.11.2005 | Xagrid | Shire Pharmaceutical Contracts Ltd, Hampshire International Business Park, Chineham, Basingstoke, Hampshire RG24 8EP, United Kingdom | EU/1/04/295/001 | 9.11.2005 |
| 7.11.2005 | Emend | Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom | EU/1/03/262/001-006 | 9.11.2005 |
| 15.11.2005 | Levitra | Bayer AG, D-51368 Leverkusen | EU/1/03/248/001-012 | 18.11.2005 |
| 15.11.2005 | Cialis - | Lilly ICOS Limited, St Bride's House — 10 Salisbury Square — London EC4Y 8EH — United Kingdom | EU/1/02/237/001-005 | 18.11.2005 |
| 15.11.2005 | Taxotere | Aventis Pharma SA, 20 avenue Raymond Aron, F-92165 Antony Cedex | EU/1/95/002/001-002 | 18.11.2005 |
| 15.11.2005 | NeuroBloc | Solstice Neurosciences Ltd, Fitzwilton House, Wilton Place, Dublin 2, Ireland | EU/1/00/166/001-003 | 21.11.2005 |
| 15.11.2005 | Vivanza — | Bayer AG, D-51368 Leverkusen | EU/1/03/249/001-012 | 18.11.2005 |
| 15.11.2005 | Viagra | Pfizer Limited, Sandwich, Kent CT13 9NJ, United Kingdom | EU/1/98/077/001-012 | 18.11.2005 |
| 15.11.2005 | PegIntron | Schering Plough Europe, Rue de Stalle, 73, B-1180 Bruxelles — Stallestraat, 73 — B-1180 Brussel | EU/1/00/131/001-050 | 18.11.2005 |
| 15.11.2005 | CellCept | Roche Registration Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom | EU/1/96/005/001-006 | 18.11.2005 |
| 15.11.2005 | Ebixa | H. Lundbeck A/S, Ottiliavej 9, DK-2500 Valby | EU/1/02/219/001-013 | 18.11.2005 |
| 15.11.2005 | Arava | Aventis Pharma Deutschland GmbH, D-65926 Frankfurt am Main | EU/1/99/118/001-010 | 18.11.2005 |
| 15.11.2005 | Avandamet | SmithKline Beecham plc, 980 Great West Road, Brentford, Middlesex,TW8 9GS United Kingdom | EU/1/03/258/001-014 | 18.11.2005 |
| 15.11.2005 | Xigris | Eli Lilly Nederland BV, Grootslag 1-5, 3991 RA Houten, Nederland | EU/1/02/225/001-002 | 18.11.2005 |
| 15.11.2005 | Emtriva | Gilead Sciences International Limited, Cambridge CB1 6GT United Kingdom | EU/1/03/261/001-003 | 18.11.2005 |
| 15.11.2005 | Viramune | Boehringer Ingelheim International GmbH, Binger Strasse 173- D — 55216 Ingelheim am Rhein | EU/1/97/055/001-003 | 18.11.2005 |
| 15.11.2005 | Tracleer | Actelion Registration Ltd, BSI Building 13th Floor, 389 Chiswick High Road, London W4 4AL, United Kingdom | EU/1/02/220/001-005 | 18.11.2005 |
| 15.11.2005 | Viraferonpeg | Schering Plough Europe, Rue de Stalle, 73, B-1180 Bruxelles — Stallestraat, 73 — B-1180 Brussel | EU/1/00/132/001-050 | 18.11.2005 |
| 15.11.2005 | Zevalin | Schering AG, Müllerstrasse 170-178, D — 13342 Berlin | EU/1/03/264/001 | 18.11.2005 |
| 15.11.2005 | Ariclaim | Boehringer Ingelheim International GmbH, Binger Strasse 173, D-55216 Ingelheim am Rhein | EU/1/04/283/001-007 | 18.11.2005 |
| 15.11.2005 | Mabthera | Roche Registration Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom | EU/1/98/067/001-002 | 18.11.2005 |
| 15.11.2005 | Advate | Baxter AG, Industriestraße 67, A-1221 Wien | EU/1/03/271/001-004 | 18.11.2005 |
| 15.11.2005 | Temodal | Schering Plough Europe, Rue de Stalle, 73, B-1180 Bruxelles | EU/1/98/096/001-008 | 18.11.2005 |
| 15.11.2005 | Somavert | Pfizer Limited, Sandwich, Kent, CT13 9NJ, United Kingdom | EU/1/02/240/001-004 | 23.11.2005 |
| 15.11.2005 | Axura | Merz Pharmaceuticals GmbH, Eckenheimer Landstr. 100-104, D-60318 Frankfurt/Main | EU/1/02/218/001-011 | 18.11.2005 |
| 16.11.2005 | NovoSeven | Novo Nordisk A/S, Novo Allé, DK-2880 Bagsvaerd | EU/1/96/006/001-003 | 21.11.2005 |
| 16.11.2005 | Truvada | Gilead Sciences International Limited, Granta Park Abington Cambridge CB1 6GT United Kingdom | EU/1/04/305/001 | 18.11.2005 |
| 17.11.2005 | Lyrica | PFIZER Ltd, Ramsgate Road, Sandwich, Kent CT 13 9NJ, United Kingdom | EU/1/04/279/001-032 | 18.11.2005 |
| 17.11.2005 | Integrilin | Glaxo Group Ltd, Berkeley Avenue, Greenford, Middlesex UB6 0NN, United Kingdom | EU/1/99/109/001-002 | 21.11.2005 |
| 17.11.2005 | Yentreve | Eli Lilly Nederland BV, Grootslag 1-5, 3991 RA Houten, Nederland | EU/1/04/280/001-007 | 21.11.2005 |
| 17.11.2005 | NeoRecormon | Roche Registration Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom | EU/1/97/031/001-003
  EU/1/97/031/019-046 | 21.11.2005 |
| 17.11.2005 | REYATAZ | Bristol — Myers Squibb Pharma EEIG, 141-149 Staines Road, Hounslow TW3 3JA, United Kingdom | EU/1/03/267/001-007 | 21.11.2005 |
| 17.11.2005 | Panretin | Ligand Pharmaceuticals UK Ltd, Innovis House, 108 High Street, Crawley, West Sussex RH10 1BB, United Kingdom | EU/1/00/149/001 | 21.11.2005 |
| 17.11.2005 | Agenerase | Glaxo Group Ltd, Greenford, Middlesex UB6 0NN, United Kingdom | EU/1/00/148/001-004 | 21.11.2005 |
| 17.11.2005 | Infanrix Hexa | GlaxoSmithKline Biologicals SA, rue de l'Institut 89, B-1330 Rixensart | EU/1/00/152/001-018 | 21.11.2005 |
| 17.11.2005 | Infanrix Penta | GlaxoSmithKline Biologicals SA, rue de l'Institut 89, B-1330 Rixensart | EU/1/00/153/001-010 | 21.11.2005 |
| 17.11.2005 | Emselex | Novartis Europharm Limited, Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom | EU/1/04/294/001-028 | 21.11.2005 |

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

7.11.2005

Abilify

Otsuka Pharmaceutical Europe Ltd, Commonwealth House, 2 Chalkhill Road, Hammersmith, London W6 8DW, United Kingdom

EU/1/04/276/001-032

9.11.2005

7.11.2005

Kivexa

Glaxo Group Ltd, Berkeley Avenue, Greenford, Middlesex UB6 0NN, United Kingdom

EU/1/04/298/001-002

9.11.2005

7.11.2005

Ziagen

Glaxo Group Ltd, Greenford, Middlesex UB6 0NN, United Kingdom

EU/1/99/112/001-002

9.11.2005

7.11.2005

Rapamune

Wyeth Europa Limited, Huntercombe Lane South, Taplow, Maidenhead, Berkshire, SL6 0PH, United Kingdom

EU/1/01/171/001-012

9.11.2005

7.11.2005

Xagrid

Shire Pharmaceutical Contracts Ltd, Hampshire International Business Park, Chineham, Basingstoke, Hampshire RG24 8EP, United Kingdom

EU/1/04/295/001

9.11.2005

7.11.2005

Emend

Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom

EU/1/03/262/001-006

9.11.2005

15.11.2005

Levitra

Bayer AG, D-51368 Leverkusen

EU/1/03/248/001-012

18.11.2005

15.11.2005

Cialis -

Lilly ICOS Limited, St Bride's House — 10 Salisbury Square — London EC4Y 8EH — United Kingdom

EU/1/02/237/001-005

18.11.2005

15.11.2005

Taxotere

Aventis Pharma SA, 20 avenue Raymond Aron, F-92165 Antony Cedex

EU/1/95/002/001-002

18.11.2005

15.11.2005

NeuroBloc

Solstice Neurosciences Ltd, Fitzwilton House, Wilton Place, Dublin 2, Ireland

EU/1/00/166/001-003

21.11.2005

15.11.2005

Vivanza —

Bayer AG, D-51368 Leverkusen

EU/1/03/249/001-012

18.11.2005

15.11.2005

Viagra

Pfizer Limited, Sandwich, Kent CT13 9NJ, United Kingdom

EU/1/98/077/001-012

18.11.2005

15.11.2005

PegIntron

Schering Plough Europe, Rue de Stalle, 73, B-1180 Bruxelles — Stallestraat, 73 — B-1180 Brussel

EU/1/00/131/001-050

18.11.2005

15.11.2005

CellCept

Roche Registration Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom

EU/1/96/005/001-006

18.11.2005

15.11.2005

Ebixa

H. Lundbeck A/S, Ottiliavej 9, DK-2500 Valby

EU/1/02/219/001-013

18.11.2005

15.11.2005

Arava

Aventis Pharma Deutschland GmbH, D-65926 Frankfurt am Main

EU/1/99/118/001-010

18.11.2005

15.11.2005

Avandamet

SmithKline Beecham plc, 980 Great West Road, Brentford, Middlesex,TW8 9GS United Kingdom

EU/1/03/258/001-014

18.11.2005

15.11.2005

Xigris

Eli Lilly Nederland BV, Grootslag 1-5, 3991 RA Houten, Nederland

EU/1/02/225/001-002

18.11.2005

15.11.2005

Emtriva

Gilead Sciences International Limited, Cambridge CB1 6GT United Kingdom

EU/1/03/261/001-003

18.11.2005

15.11.2005

Viramune

Boehringer Ingelheim International GmbH, Binger Strasse 173- D — 55216 Ingelheim am Rhein

EU/1/97/055/001-003

18.11.2005

15.11.2005

Tracleer

Actelion Registration Ltd, BSI Building 13th Floor, 389 Chiswick High Road, London W4 4AL, United Kingdom

EU/1/02/220/001-005

18.11.2005

15.11.2005

Viraferonpeg

Schering Plough Europe, Rue de Stalle, 73, B-1180 Bruxelles — Stallestraat, 73 — B-1180 Brussel

EU/1/00/132/001-050

18.11.2005

15.11.2005

Zevalin

Schering AG, Müllerstrasse 170-178, D — 13342 Berlin

EU/1/03/264/001

18.11.2005

15.11.2005

Ariclaim

Boehringer Ingelheim International GmbH, Binger Strasse 173, D-55216 Ingelheim am Rhein

EU/1/04/283/001-007

18.11.2005

15.11.2005

Mabthera

Roche Registration Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom

EU/1/98/067/001-002

18.11.2005

15.11.2005

Advate

Baxter AG, Industriestraße 67, A-1221 Wien

EU/1/03/271/001-004

18.11.2005

15.11.2005

Temodal

Schering Plough Europe, Rue de Stalle, 73, B-1180 Bruxelles

EU/1/98/096/001-008

18.11.2005

15.11.2005

Somavert

Pfizer Limited, Sandwich, Kent, CT13 9NJ, United Kingdom

EU/1/02/240/001-004

23.11.2005

15.11.2005

Axura

Merz Pharmaceuticals GmbH, Eckenheimer Landstr. 100-104, D-60318 Frankfurt/Main

EU/1/02/218/001-011

18.11.2005

16.11.2005

NovoSeven

Novo Nordisk A/S, Novo Allé, DK-2880 Bagsvaerd

EU/1/96/006/001-003

21.11.2005

16.11.2005

Truvada

Gilead Sciences International Limited, Granta Park Abington Cambridge CB1 6GT United Kingdom

EU/1/04/305/001

18.11.2005

17.11.2005

Lyrica

PFIZER Ltd, Ramsgate Road, Sandwich, Kent CT 13 9NJ, United Kingdom

EU/1/04/279/001-032

18.11.2005

17.11.2005

Integrilin

Glaxo Group Ltd, Berkeley Avenue, Greenford, Middlesex UB6 0NN, United Kingdom

EU/1/99/109/001-002

21.11.2005

17.11.2005

Yentreve

Eli Lilly Nederland BV, Grootslag 1-5, 3991 RA Houten, Nederland

EU/1/04/280/001-007

21.11.2005

17.11.2005

NeoRecormon

Roche Registration Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom

EU/1/97/031/001-003

EU/1/97/031/019-046

21.11.2005

17.11.2005

REYATAZ

Bristol — Myers Squibb Pharma EEIG, 141-149 Staines Road, Hounslow TW3 3JA, United Kingdom

EU/1/03/267/001-007

21.11.2005

17.11.2005

Panretin

Ligand Pharmaceuticals UK Ltd, Innovis House, 108 High Street, Crawley, West Sussex RH10 1BB, United Kingdom

EU/1/00/149/001

21.11.2005

17.11.2005

Agenerase

Glaxo Group Ltd, Greenford, Middlesex UB6 0NN, United Kingdom

EU/1/00/148/001-004

21.11.2005

17.11.2005

Infanrix Hexa

GlaxoSmithKline Biologicals SA, rue de l'Institut 89, B-1330 Rixensart

EU/1/00/152/001-018

21.11.2005

17.11.2005

Infanrix Penta

GlaxoSmithKline Biologicals SA, rue de l'Institut 89, B-1330 Rixensart

EU/1/00/153/001-010

21.11.2005

17.11.2005

Emselex

Novartis Europharm Limited, Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom

EU/1/04/294/001-028

21.11.2005

—   Suspension of a marketing authorization (Article 18 of Council Regulation (EEC) No 2309/93)

| Date of the decision | Name of the medicinal product | Holder of the marketing authorization | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 17.11.2005 | Hexavac | Sanofi Pasteur MSD, SNC, 8, rue Jonas Salk, F-69007 Lyon | EU/1/00/147/001-012 | 21.11.2005 |

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

17.11.2005

Hexavac

Sanofi Pasteur MSD, SNC, 8, rue Jonas Salk, F-69007 Lyon

EU/1/00/147/001-012

21.11.2005

—   Modification of a marketing authorization (Article 34 of Council Regulation (EEC) No 2309/93): Accepted

| Date of the decision | Name of the medicinal product | Holder of the marketing authorization | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 17.11.2005 | Pruban | Intervet International BV, Wim de Körverstraat 35, 5831 AN Boxmeer, Nederland | EU/2/00/024/001 | 21.11.2005 |

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

17.11.2005

Pruban

Intervet International BV, Wim de Körverstraat 35, 5831 AN Boxmeer, Nederland

EU/2/00/024/001

21.11.2005

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

| The European Medicines Agency |
| --- |
| 7 Westferry Circus, Canary Wharf |
| London E14 4HB |
| United Kingdom |

The European Medicines Agency

7 Westferry Circus, Canary Wharf

London E14 4HB

United Kingdom

---

(1)  OJ L 214, 24.8.1993, p. 1.

---

| 30.12.2005 | EN | Official Journal of the European Union | C 334/35 |
| --- | --- | --- | --- |

30.12.2005

EN

Official Journal of the European Union

C 334/35

---

Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 November 2005 to 19 November 2005

(Decisions taken pursuant to Article 34 of Directive 2001/83/EC (1) or Article 38 of Directive 2001/82/EC (2))

(2005/C 334/07)

Issuing, maintenance or modification of a national marketing authorisation

| Date of the decision | Name(s) of the medicinal product | Holder(s) of the marketing authorization | Member State concerned | Date of notification |
| --- | --- | --- | --- | --- |
| 7.11.2005 | Coversyl | See Annex | See Annex | 24.11.2005 |

Date of the decision

Name(s) of the medicinal product

Holder(s) of the marketing authorization

Member State concerned

Date of notification

7.11.2005

Coversyl

See Annex

See Annex

24.11.2005

---

(1)  OJ L 311, 28.11.2001, p. 67.

(2)  OJ L 311, 28.11.2001, p. 1.

---

ANNEX

LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES

| Member State | Marketing Authorisation Holder | Invented name | Strength | Pharmaceutical form | Route of administration |
| --- | --- | --- | --- | --- | --- |
| Austria | Servier Austria GmbH | COVERSUM | 2 mg | Tablets | Oral use |
| Austria | Servier Austria GmbH | COVERSUM | 4 mg | Tablets | Oral use |
| Belgium | Servier Benelux S.A. | COVERSYL | 2 mg | Tablets | Oral use |
| Belgium | Servier Benelux S.A. | COVERSYL | 4 mg | Tablets | Oral use |
| Denmark | Les Laboratoires Servier | COVERSYL | 2 mg | Tablets | Oral use |
| Denmark | Les Laboratoires Servier | COVERSYL | 4 mg | Tablets | Oral use |
| Finland | Les Laboratoires Servier | COVERSYL | 2 mg | Tablets | Oral use |
| Finland | Les Laboratoires Servier | COVERSYL | 4 mg | Tablets | Oral use |
| France | Les Laboratoires Servier | COVERSYL | 2 mg | Tablets | Oral use |
| France | Les Laboratoires Servier | COVERSYL | 4 mg | Tablets | Oral use |
| Germany | Les Laboratoires Servier | COVERSUM COR | 2 mg | Tablets | Oral use |
| Germany | Les Laboratoires Servier | COVERSUM | 4 mg | Tablets | Oral use |
| Greece | Servier Hellas Pharmaceuticals S.A. | COVERSYL | 2 mg | Tablets | Oral use |
| Greece | Servier Hellas Pharmaceuticals S.A. | COVERSYL | 4 mg | Tablets | Oral use |
| Iceland | Les Laboratoires Servier | COVERSYL | 2 mg | Tablets | Oral use |
| Iceland | Les Laboratoires Servier | COVERSYL | 4 mg | Tablets | Oral use |
| Ireland | Les Laboratoires Servier | COVERSYL | 2 mg | Tablets | Oral use |
| Ireland | Les Laboratoires Servier | COVERSYL | 4 mg | Tablets | Oral use |
| Italy | Les Laboratoires Servier | COVERSYL | 4 mg | Tablets | Oral use |
| Luxembourg | Servier Benelux S.A. | COVERSYL | 2 mg | Tablets | Oral use |
| Luxembourg | Servier Benelux S.A. | COVERSYL | 4 mg | Tablets | Oral use |
| Netherlands | Les Laboratoires Servier | COVERSYL | 2 mg | Tablets | Oral use |
| Netherlands | Les Laboratoires Servier | COVERSYL | 4 mg | Tablets | Oral use |
| Norway | Les Laboratoires Servier | COVERSYL | 2 mg | Tablets | Oral use |
| Norway | Les Laboratoires Servier | COVERSYL | 4 mg | Tablets | Oral use |
| Portugal | Servier Portugal — Especialidades Farmacêuticas | COVERSYL | 2 mg | Tablets | Oral use |
| Portugal | Servier Portugal — Especialidades Farmacêuticas | COVERSYL | 4 mg | Tablets | Oral use |
| Spain | Les Laboratoires Servier | COVERSYL | 4 mg | Tablets | Oral use |
| Sweden | Les Laboratoires Servier | COVERSYL | 2 mg | Tablets | Oral use |
| Sweden | Les Laboratoires Servier | COVERSYL | 4 mg | Tablets | Oral use |
| United Kingdom | Les Laboratoires Servier | COVERSYL | 2 mg | Tablets | Oral use |
| United Kingdom | Les Laboratoires Servier | COVERSYL | 4 mg | Tablets | Oral use |

Member State

Marketing Authorisation Holder

Invented name

Strength

Pharmaceutical form

Route of administration

Austria

Servier Austria GmbH

COVERSUM

2 mg

Tablets

Oral use

Austria

Servier Austria GmbH

COVERSUM

4 mg

Tablets

Oral use

Belgium

Servier Benelux S.A.

COVERSYL

2 mg

Tablets

Oral use

Belgium

Servier Benelux S.A.

COVERSYL

4 mg

Tablets

Oral use

Denmark

Les Laboratoires Servier

COVERSYL

2 mg

Tablets

Oral use

Denmark

Les Laboratoires Servier

COVERSYL

4 mg

Tablets

Oral use

Finland

Les Laboratoires Servier

COVERSYL

2 mg

Tablets

Oral use

Finland

Les Laboratoires Servier

COVERSYL

4 mg

Tablets

Oral use

France

Les Laboratoires Servier

COVERSYL

2 mg

Tablets

Oral use

France

Les Laboratoires Servier

COVERSYL

4 mg

Tablets

Oral use

Germany

Les Laboratoires Servier

COVERSUM COR

2 mg

Tablets

Oral use

Germany

Les Laboratoires Servier

COVERSUM

4 mg

Tablets

Oral use

Greece

Servier Hellas Pharmaceuticals S.A.

COVERSYL

2 mg

Tablets

Oral use

Greece

Servier Hellas Pharmaceuticals S.A.

COVERSYL

4 mg

Tablets

Oral use

Iceland

Les Laboratoires Servier

COVERSYL

2 mg

Tablets

Oral use

Iceland

Les Laboratoires Servier

COVERSYL

4 mg

Tablets

Oral use

Ireland

Les Laboratoires Servier

COVERSYL

2 mg

Tablets

Oral use

Ireland

Les Laboratoires Servier

COVERSYL

4 mg

Tablets

Oral use

Italy

Les Laboratoires Servier

COVERSYL

4 mg

Tablets

Oral use

Luxembourg

Servier Benelux S.A.

COVERSYL

2 mg

Tablets

Oral use

Luxembourg

Servier Benelux S.A.

COVERSYL

4 mg

Tablets

Oral use

Netherlands

Les Laboratoires Servier

COVERSYL

2 mg

Tablets

Oral use

Netherlands

Les Laboratoires Servier

COVERSYL

4 mg

Tablets

Oral use

Norway

Les Laboratoires Servier

COVERSYL

2 mg

Tablets

Oral use

Norway

Les Laboratoires Servier

COVERSYL

4 mg

Tablets

Oral use

Portugal

Servier Portugal — Especialidades Farmacêuticas

COVERSYL

2 mg

Tablets

Oral use

Portugal

Servier Portugal — Especialidades Farmacêuticas

COVERSYL

4 mg

Tablets

Oral use

Spain

Les Laboratoires Servier

COVERSYL

4 mg

Tablets

Oral use

Sweden

Les Laboratoires Servier

COVERSYL

2 mg

Tablets

Oral use

Sweden

Les Laboratoires Servier

COVERSYL

4 mg

Tablets

Oral use

United Kingdom

Les Laboratoires Servier

COVERSYL

2 mg

Tablets

Oral use

United Kingdom

Les Laboratoires Servier

COVERSYL

4 mg

Tablets

Oral use

---

| 30.12.2005 | EN | Official Journal of the European Union | C 334/38 |
| --- | --- | --- | --- |

30.12.2005

EN

Official Journal of the European Union

C 334/38

---

Summary of Community decisions on marketing authorizations in respect of medicinal products from 20 November 2005 to 30 November 2005

(Decisions taken pursuant to Article 34 of Directive 2001/83/EC (1) or Article 38 of Directive 2001/82/EC (2))

(2005/C 334/08)

Issuing, maintenance or modification of a national marketing authorisation

| Date of the decision | Name(s) of the medicinal product | Holder(s) of the marketing authorization | Member State concerned | Date of notification |
| --- | --- | --- | --- | --- |
| 28.11.2005 | Celocoxib | See Annex I | See Annex I | 29.11.2005 |
| 28.11.2005 | Etoricoxib | See Annex II | See Annex II | 29.11.2005 |
| 28.11.2005 | Lumiracoxib | See Annex III | See Annex III | 29.11.2005 |

Date of the decision

Name(s) of the medicinal product

Holder(s) of the marketing authorization

Member State concerned

Date of notification

28.11.2005

Celocoxib

See Annex I

See Annex I

29.11.2005

28.11.2005

Etoricoxib

See Annex II

See Annex II

29.11.2005

28.11.2005

Lumiracoxib

See Annex III

See Annex III

29.11.2005

---

(1)  OJ L 311, 28.11.2001, p. 67.

(2)  OJ L 311, 28.11.2001, p. 1.

---

ANNEX I

LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES AND NORWAY AND ICELAND

| Member State | Marketing Authorisation Holder | Invented name | Strength | Pharmaceutical Form | Route of administration |
| --- | --- | --- | --- | --- | --- |
| Österreich | Pfizer Corporation Austria Ges.m.b.H.
  Seidengasse 33-35
  A-1071 Wien | Celebrex | 100 mg | Capsules | Oral |
| Pfizer Corporation Austria Ges.m.b.H.
  Seidengasse 33-35
  A-1071 Wien | Celebrex | 200 mg | Capsules | Oral |
| Pfizer Corporation Austria Ges.m.b.H.
  Seidengasse 33-35
  A-1071 Wien | Solexa | 100 mg | Capsules | Oral |
| Pfizer Corporation Austria Ges.m.b.H.
  Seidengasse 33-35
  A-1071 Wien | Solexa | 200 mg | Capsules | Oral |
| Belgique/België | Pharmacia NV/SA
  Rijksweg 12
  B-2870 Puurs | Celebrex | 100 mg | Capsules | Oral |
| Pharmacia NV/SA
  Rijksweg 12
  B-2870 Puurs | Celebrex | 200 mg | Capsules | Oral |
| Pharmacia NV/SA
  Rijksweg 12
  B-2870 Puurs | Solexa | 100 mg | Capsules | Oral |
| Pharmacia NV/SA
  Rijksweg 12
  B-2870 Puurs | Solexa | 200 mg | Capsules | Oral |
| Κύπρος | Markides & Vouros Ltd.
  5a-B Pargas Str
  P.O.Box 22002
  1515 Lefkosia
  Cyprus | Celebrex | 100 mg | Capsules | Oral |
| Markides & Vouros Ltd.
  5a-B Pargas Str
  P.O.Box 22002
  1515 Lefkosia
  Cyprus | Celebrex | 200 mg | Capsules | Oral |
| Česká republika | Pharmacia Ltd.
  Davy Avenue
  Know Hill
  Milton Keynes MK5 8PH
  United Kingdom | Celebrex | 100 mg | Capsules | Oral |
| Pharmacia Ltd.
  Davy Avenue
  Know Hill
  Milton Keynes MK5 8PH
  United Kingdom | Celebrex | 200 mg | Capsules | Oral |
| Danmark | Pfizer ApS
  Lautrupvang 8
  DK-2750 Ballerup | Celebra | 100 mg | Capsules | Oral |
| Pfizer ApS
  Lautrupvang 8
  DK-2750 Ballerup | Celebra | 200 mg | Capsules | Oral |
| Pfizer ApS
  Lautrupvang 8
  DK-2750 Ballerup | Solexa | 100 mg | Capsules | Oral |
| Pfizer ApS
  Lautrupvang 8
  DK-2750 Ballerup | Solexa | 200 mg | Capsules | Oral |
| Eesti | Pfizer H.C.P. Corporation Eesti
  Pirita tee 20
  EE-10127 Tallinn | Celebrex | 100 mg | Capsules | Oral |
| Pfizer H.C.P. Corporation Eesti
  Pirita tee 20
  EE-10127 Tallinn | Celebrex | 200 mg | Capsules | Oral |
| Suomi | Pfizer Oy
  Tietokuja 4
  FIN-00330 Helsinki | Celebra | 100 mg | Capsules | Oral |
| Pfizer Oy
  Tietokuja 4
  FIN-00330 Helsinki | Celebra | 200 mg | Capsules | Oral |
| Pfizer Oy
  Tietokuja 4
  FIN-00330 Helsinki | Solexa | 100 mg | Capsules | Oral |
| Pfizer Oy
  Tietokuja 4
  FIN-00330 Helsinki | Solexa | 200 mg | Capsules | Oral |
| France | Pfizer Holding France
  23-25, avenue du Docteur Lannelongue
  F-75668 Paris Cedex 14 | Celebrex | 100 mg | Capsules | Oral |
| Pfizer Holding France
  23-25, avenue du Docteur Lannelongue
  F-75668 Paris Cedex 14 | Celebrex | 200 mg | Capsules | Oral |
| Cardel
  23-25, avenue du Docteur Lannelongue
  F-75668 Paris Cedex 14 | Solexa | 100 mg | Capsules | Oral |
| Cardel
  23-25, avenue du Docteur Lannelongue
  F-75668 Paris Cedex 14 | Solexa | 200 mg | Capsules | Oral |
| Deutschland | Pharmacia GmbH
  Pfizerstr. 1
  D-76139 Karlsruhe | Celebra | 200 mg | Capsules | Oral |
| Pharmacia GmbH
  Pfizerstr. 1
  D-76139 Karlsruhe | Celebra | 100 mg | Capsules | Oral |
| Pharmacia GmbH
  Pfizerstr. 1
  D-76139 Karlsruhe | Celebrex | 200 mg | Capsules | Oral |
| Pharmacia GmbH
  Pfizerstr. 1
  D-76139 Karlsruhe | Celebrex | 100 mg | Capsules | Oral |
| Ελλάδα | Pfizer Hellas A.E.
  5, Alketou Street
  GR-116 33 Athens | Celebrex | 100 mg | Capsules | Oral |
| Pfizer Hellas A.E.
  5, Alketou Street
  GR-116 33 Athens | Celebrex | 200 mg | Capsules | Oral |
| Pfizer Hellas A.E.
  5, Alketou Street
  GR-116 33 Athens | Aclarex | 100 mg | Capsules | Oral |
| Pfizer Hellas A.E.
  5, Alketou Street
  GR-116 33 Athens | Aclarex | 200 mg | Capsules | Oral |
| Magyarország | Pfizer Kft.
  Alkotás utca 53. MOM Park ‘F’ Épület
  H-1123 Budapest | Celebrex | 200 mg | Capsules | Oral |
| Island | Pfizer ApS
  Lautrupvang 8
  DK-2750 Ballerup | Celebra | 100 mg | Capsules | Oral |
| Pfizer ApS
  Lautrupvang 8
  DK-2750 Ballerup | Celebra | 200 mg | Capsules | Oral |
| Ireland | Pharmacia Ireland Limited
  Airways Industrial Estate
  Dublin 17
  Ireland | Celebrex | 100 mg | Capsules | Oral |
| Pharmacia Ireland Limited
  Airways Industrial Estate
  Dublin 17
  Ireland | Celebrex | 200 mg | Capsules | Oral |
| Pharmacia Ireland Limited
  Airways Industrial Estate
  Dublin 17
  Ireland | Solexa | 100 mg | Capsules | Oral |
| Pharmacia Ireland Limited
  Airways Industrial Estate
  Dublin 17
  Ireland | Solexa | 200 mg | Capsules | Oral |
| Italia | Pharmacia Italia S.p.A.
  Via Robert Koch, 1-2
  I-20152 Milano | Artilog | 100 mg | Capsules | Oral |
| Pharmacia Italia S.p.A.
  Via Robert Koch, 1-2
  I-20152 Milano | Artilog | 200 mg | Capsules | Oral |
| Sefarma S.r.l.
  Via Robert Koch, 1-2
  I-20152 Milano | Artrid | 100 mg | Capsules | Oral |
| Sefarma S.r.l.
  Via Robert Koch, 1-2
  I-20152 Milano | Artrid | 200 mg | Capsules | Oral |
| Pfizer Italia S.r.l.
  Strada Statale 156 KM 50
  I-04010 Borgo San Michele, Latina | Solexa | 100 mg | Capsules | Oral |
| Pfizer Italia S.r.l.
  Strada Statale 156 KM 50
  I-04010 Borgo San Michele, Latina | Solexa | 200 mg | Capsules | Oral |
| Pharmacia Italia S.p.A.
  Via Robert Koch, 1-2
  I-20152 Milano | Celebrex | 100 mg | Capsules | Oral |
| Pharmacia Italia S.p.A.
  Via Robert Koch, 1-2
  I-20152 Milano | Celebrex | 200 mg | Capsules | Oral |
| Latvija | Pfizer Ltd.
  Ramsgate Road
  Sandwich
  Kent CT13 9NJ
  United Kingdom | Celebrex | 100 mg | Capsules | Oral |
| Pfizer Ltd.
  Ramsgate Road
  Sandwich
  Kent CT13 9NJ
  United Kingdom | Celebrex | 200 mg | Capsules | Oral |
| Lietuva | Pfizer H.C.P. Corporation
  Representation Office in Lithuania
  A. Gostauto 40 a
  LT-01112 Vilnius | Celebrex | 100 mg | Capsules | Oral |
| Pfizer H.C.P. Corporation
  Representation Office in Lithuania
  A. Gostauto 40 a
  LT-01112 Vilnius | Celebrex | 200 mg | Capsules | Oral |
| Luxembourg | Pharmacia NV/SA
  Rijksweg 12
  B-2870 Puurs | Celebrex | 100 mg | Capsules | Oral |
| Pharmacia NV/SA
  Rijksweg 12
  B-2870 Puurs | Celebrex | 200 mg | Capsules | Oral |
| Pharmacia NV/SA
  Rijksweg 12
  B-2870 Puurs | Solexa | 100 mg | Capsules | Oral |
| Pharmacia NV/SA
  Rijksweg 12
  B-2870 Puurs | Solexa | 200 mg | Capsules | Oral |
| Malta | Pfizer Hellas A. E.
  5, Alketou Street
  GR-116 33 Athens | Celebrex | 100 mg | Capsules | Oral |
| Pfizer Hellas A. E.
  5, Alketou Street
  GR-116 33 Athens | Celebrex | 200 mg | Capsules | Oral |
| Norge | Pfizer AS
  Postboks 3
  N-1324 Lysaker | Celebra | 100 mg | Capsules | Oral |
| Pfizer AS
  Postboks 3
  N-1324 Lysaker | Celebra | 200 mg | Capsules | Oral |
| Polska | Pharmacia Ltd.
  Ramsgate Road
  Sandwich
  Kent CT13 9NJ
  United Kingdom | Celebrex | 100 mg | Capsules | Oral |
| Pharmacia Ltd.
  Ramsgate Road
  Sandwich
  Kent CT13 9NJ
  United Kingdom | Celebrex | 200 mg | Capsules | Oral |
| Portugal | Laboratórios Pfizer, Lda.
  Lagoas Park, Edifício n.o 10
  P-2740-244 Porto Salvo | Celebrex | 100 mg | Capsules | Oral |
| Laboratórios Pfizer, Lda.
  Lagoas Park, Edifício n.o 10
  P-2740-244 Porto Salvo | Celebrex | 200 mg | Capsules | Oral |
| Lab. Medinfar — Produtos Farmacêuticos S.A.
  R. Manuel Ribeiro de Pavia, n.o 1 — Venda Nova
  P-2700-547 Amadora | Solexa | 100 mg | Capsules | Oral |
| Lab. Medinfar — Produtos Farmacêuticos S.A.
  R. Manuel Ribeiro de Pavia, n.o 1 — Venda Nova
  P-2700-547 Amadora | Solexa | 200 mg | Capsules | Oral |
| Slovenská republika | Pfizer Europe MA EEIG
  Ramsgate Road
  Sandwich
  Kent CT13 9NJ
  United Kingdom | Celebrex | 100 mg | Capsules | Oral |
| Pfizer Europe MA EEIG
  Ramsgate Road
  Sandwich
  Kent CT13 9NJ
  United Kingdom | Celebrex | 200 mg | Capsules | Oral |
| Slovenija | Pfizer Luxembourg SARL
  283, route d'Arlon
  L-8011 Strassen | Celebrex | 100 mg | Capsules | Oral |
| Pfizer Luxembourg SARL
  283, route d'Arlon
  L-8011 Strassen | Celebrex | 200 mg | Capsules | Oral |
| España | Pharmacia Spain S.A.
  Avenida de Europa, 20-B
  Parque Empresarial La Moraleja
  E-28108 Alcobendas, Madrid | Celebrex | 100 mg | Capsules | Oral |
| Pharmacia Spain S.A.
  Avenida de Europa, 20-B
  Parque Empresarial La Moraleja
  E-28108 Alcobendas, Madrid | Artilog | 100 mg | Capsules | Oral |
| Pharmacia Spain S.A.
  Avenida de Europa, 20-B
  Parque Empresarial La Moraleja
  E-28108 Alcobendas, Madrid | Celebrex | 200 mg | Capsules | Oral |
| Pharmacia Spain S.A.
  Avenida de Europa, 20-B
  Parque Empresarial La Moraleja
  E-28108 Alcobendas, Madrid | Artilog | 200 mg | Capsules | Oral |
| Sverige | Pfizer AB
  Nytorpsvägen 36
  P.O. Box 501
  S-183 25 Täby | Celebra | 100 mg | Capsules | Oral |
| Pfizer AB
  Nytorpsvägen 36
  P.O. Box 501
  S-183 25 Täby | Celebra | 200 mg | Capsules | Oral |
| Pfizer AB
  Nytorpsvägen 36
  P.O. Box 501
  S-183 25 Täby | Solexa | 100 mg | Capsules | Oral |
| Pfizer AB
  Nytorpsvägen 36
  P.O. Box 501
  S-183 25 Täby | Solexa | 200 mg | Capsules | Oral |
| Pfizer AB
  Nytorpsvägen 36
  P.O. Box 501
  S-183 25 Täby | Celora | 100 mg | Capsules | Oral |
| Pfizer AB
  Nytorpsvägen 36
  P.O. Box 501
  S-183 25 Täby | Celora | 200 mg | Capsules | Oral |
| Pfizer AB
  Nytorpsvägen 36
  P.O. Box 501
  S-183 25 Täby | Aclarix | 100 mg | Capsules | Oral |
| Pfizer AB
  Nytorpsvägen 36
  P.O. Box 501
  S-183 25 Täby | Aclarix | 200 mg | Capsules | Oral |
| Nederland | Pfizer bv
  Rivium Westlaan 142
  2909 LD Capelle a/d IJssel
  Nederland | Celebrex | 100 mg | Capsules | Oral |
| Pfizer bv
  Rivium Westlaan 142
  2909 LD Capelle a/d IJssel
  Nederland | Celebrex | 200 mg | Capsules | Oral |
| Pfizer bv
  Rivium Westlaan 142
  2909 LD Capelle a/d IJssel
  Nederland | Solexa | 100 mg | Capsules | Oral |
| Pfizer bv
  Rivium Westlaan 142
  2909 LD Capelle a/d IJssel
  Nederland | Solexa | 200 mg | Capsules | Oral |
| United Kingdom | Pfizer Ltd.
  Ramsgate Road
  Sandwich
  Kent CT13 9NJ
  United Kingdom | Celebrex | 100 mg | Capsules | Oral |
| Pfizer Ltd.
  Ramsgate Road
  Sandwich
  Kent CT13 9NJ
  United Kingdom | Celebrex | 200 mg | Capsules | Oral |
| Pfizer Ltd.
  Ramsgate Road
  Sandwich
  Kent CT13 9NJ
  United Kingdom | Solexa | 100 mg | Capsules | Oral |
| Pfizer Ltd.
  Ramsgate Road
  Sandwich
  Kent CT13 9NJ
  United Kingdom | Solexa | 200 mg | Capsules | Oral |

Member State

Marketing Authorisation Holder

Invented name

Strength

Pharmaceutical Form

Route of administration

Österreich

Pfizer Corporation Austria Ges.m.b.H.

Seidengasse 33-35

A-1071 Wien

Celebrex

100 mg

Capsules

Oral

Pfizer Corporation Austria Ges.m.b.H.

Seidengasse 33-35

A-1071 Wien

Celebrex

200 mg

Capsules

Oral

Pfizer Corporation Austria Ges.m.b.H.

Seidengasse 33-35

A-1071 Wien

Solexa

100 mg

Capsules

Oral

Pfizer Corporation Austria Ges.m.b.H.

Seidengasse 33-35

A-1071 Wien

Solexa

200 mg

Capsules

Oral

Belgique/België

Pharmacia NV/SA

Rijksweg 12

B-2870 Puurs

Celebrex

100 mg

Capsules

Oral

Pharmacia NV/SA

Rijksweg 12

B-2870 Puurs

Celebrex

200 mg

Capsules

Oral

Pharmacia NV/SA

Rijksweg 12

B-2870 Puurs

Solexa

100 mg

Capsules

Oral

Pharmacia NV/SA

Rijksweg 12

B-2870 Puurs

Solexa

200 mg

Capsules

Oral

Κύπρος

Markides & Vouros Ltd.

5a-B Pargas Str

P.O.Box 22002

1515 Lefkosia

Cyprus

Celebrex

100 mg

Capsules

Oral

Markides & Vouros Ltd.

5a-B Pargas Str

P.O.Box 22002

1515 Lefkosia

Cyprus

Celebrex

200 mg

Capsules

Oral

Česká republika

Pharmacia Ltd.

Davy Avenue

Know Hill

Milton Keynes MK5 8PH

United Kingdom

Celebrex

100 mg

Capsules

Oral

Pharmacia Ltd.

Davy Avenue

Know Hill

Milton Keynes MK5 8PH

United Kingdom

Celebrex

200 mg

Capsules

Oral

Danmark

Pfizer ApS

Lautrupvang 8

DK-2750 Ballerup

Celebra

100 mg

Capsules

Oral

Pfizer ApS

Lautrupvang 8

DK-2750 Ballerup

Celebra

200 mg

Capsules

Oral

Pfizer ApS

Lautrupvang 8

DK-2750 Ballerup

Solexa

100 mg

Capsules

Oral

Pfizer ApS

Lautrupvang 8

DK-2750 Ballerup

Solexa

200 mg

Capsules

Oral

Eesti

Pfizer H.C.P. Corporation Eesti

Pirita tee 20

EE-10127 Tallinn

Celebrex

100 mg

Capsules

Oral

Pfizer H.C.P. Corporation Eesti

Pirita tee 20

EE-10127 Tallinn

Celebrex

200 mg

Capsules

Oral

Suomi

Pfizer Oy

Tietokuja 4

FIN-00330 Helsinki

Celebra

100 mg

Capsules

Oral

Pfizer Oy

Tietokuja 4

FIN-00330 Helsinki

Celebra

200 mg

Capsules

Oral

Pfizer Oy

Tietokuja 4

FIN-00330 Helsinki

Solexa

100 mg

Capsules

Oral

Pfizer Oy

Tietokuja 4

FIN-00330 Helsinki

Solexa

200 mg

Capsules

Oral

France

Pfizer Holding France

23-25, avenue du Docteur Lannelongue

F-75668 Paris Cedex 14

Celebrex

100 mg

Capsules

Oral

Pfizer Holding France

23-25, avenue du Docteur Lannelongue

F-75668 Paris Cedex 14

Celebrex

200 mg

Capsules

Oral

Cardel

23-25, avenue du Docteur Lannelongue

F-75668 Paris Cedex 14

Solexa

100 mg

Capsules

Oral

Cardel

23-25, avenue du Docteur Lannelongue

F-75668 Paris Cedex 14

Solexa

200 mg

Capsules

Oral

Deutschland

Pharmacia GmbH

Pfizerstr. 1

D-76139 Karlsruhe

Celebra

200 mg

Capsules

Oral

Pharmacia GmbH

Pfizerstr. 1

D-76139 Karlsruhe

Celebra

100 mg

Capsules

Oral

Pharmacia GmbH

Pfizerstr. 1

D-76139 Karlsruhe

Celebrex

200 mg

Capsules

Oral

Pharmacia GmbH

Pfizerstr. 1

D-76139 Karlsruhe

Celebrex

100 mg

Capsules

Oral

Ελλάδα

Pfizer Hellas A.E.

5, Alketou Street

GR-116 33 Athens

Celebrex

100 mg

Capsules

Oral

Pfizer Hellas A.E.

5, Alketou Street

GR-116 33 Athens

Celebrex

200 mg

Capsules

Oral

Pfizer Hellas A.E.

5, Alketou Street

GR-116 33 Athens

Aclarex

100 mg

Capsules

Oral

Pfizer Hellas A.E.

5, Alketou Street

GR-116 33 Athens

Aclarex

200 mg

Capsules

Oral

Magyarország

Pfizer Kft.

Alkotás utca 53. MOM Park ‘F’ Épület

H-1123 Budapest

Celebrex

200 mg

Capsules

Oral

Island

Pfizer ApS

Lautrupvang 8

DK-2750 Ballerup

Celebra

100 mg

Capsules

Oral

Pfizer ApS

Lautrupvang 8

DK-2750 Ballerup

Celebra

200 mg

Capsules

Oral

Ireland

Pharmacia Ireland Limited

Airways Industrial Estate

Dublin 17

Ireland

Celebrex

100 mg

Capsules

Oral

Pharmacia Ireland Limited

Airways Industrial Estate

Dublin 17

Ireland

Celebrex

200 mg

Capsules

Oral

Pharmacia Ireland Limited

Airways Industrial Estate

Dublin 17

Ireland

Solexa

100 mg

Capsules

Oral

Pharmacia Ireland Limited

Airways Industrial Estate

Dublin 17

Ireland

Solexa

200 mg

Capsules

Oral

Italia

Pharmacia Italia S.p.A.

Via Robert Koch, 1-2

I-20152 Milano

Artilog

100 mg

Capsules

Oral

Pharmacia Italia S.p.A.

Via Robert Koch, 1-2

I-20152 Milano

Artilog

200 mg

Capsules

Oral

Sefarma S.r.l.

Via Robert Koch, 1-2

I-20152 Milano

Artrid

100 mg

Capsules

Oral

Sefarma S.r.l.

Via Robert Koch, 1-2

I-20152 Milano

Artrid

200 mg

Capsules

Oral

Pfizer Italia S.r.l.

Strada Statale 156 KM 50

I-04010 Borgo San Michele, Latina

Solexa

100 mg

Capsules

Oral

Pfizer Italia S.r.l.

Strada Statale 156 KM 50

I-04010 Borgo San Michele, Latina

Solexa

200 mg

Capsules

Oral

Pharmacia Italia S.p.A.

Via Robert Koch, 1-2

I-20152 Milano

Celebrex

100 mg

Capsules

Oral

Pharmacia Italia S.p.A.

Via Robert Koch, 1-2

I-20152 Milano

Celebrex

200 mg

Capsules

Oral

Latvija

Pfizer Ltd.

Ramsgate Road

Sandwich

Kent CT13 9NJ

United Kingdom

Celebrex

100 mg

Capsules

Oral

Pfizer Ltd.

Ramsgate Road

Sandwich

Kent CT13 9NJ

United Kingdom

Celebrex

200 mg

Capsules

Oral

Lietuva

Pfizer H.C.P. Corporation

Representation Office in Lithuania

A. Gostauto 40 a

LT-01112 Vilnius

Celebrex

100 mg

Capsules

Oral

Pfizer H.C.P. Corporation

Representation Office in Lithuania

A. Gostauto 40 a

LT-01112 Vilnius

Celebrex

200 mg

Capsules

Oral

Luxembourg

Pharmacia NV/SA

Rijksweg 12

B-2870 Puurs

Celebrex

100 mg

Capsules

Oral

Pharmacia NV/SA

Rijksweg 12

B-2870 Puurs

Celebrex

200 mg

Capsules

Oral

Pharmacia NV/SA

Rijksweg 12

B-2870 Puurs

Solexa

100 mg

Capsules

Oral

Pharmacia NV/SA

Rijksweg 12

B-2870 Puurs

Solexa

200 mg

Capsules

Oral

Malta

Pfizer Hellas A. E.

5, Alketou Street

GR-116 33 Athens

Celebrex

100 mg

Capsules

Oral

Pfizer Hellas A. E.

5, Alketou Street

GR-116 33 Athens

Celebrex

200 mg

Capsules

Oral

Norge

Pfizer AS

Postboks 3

N-1324 Lysaker

Celebra

100 mg

Capsules

Oral

Pfizer AS

Postboks 3

N-1324 Lysaker

Celebra

200 mg

Capsules

Oral

Polska

Pharmacia Ltd.

Ramsgate Road

Sandwich

Kent CT13 9NJ

United Kingdom

Celebrex

100 mg

Capsules

Oral

Pharmacia Ltd.

Ramsgate Road

Sandwich

Kent CT13 9NJ

United Kingdom

Celebrex

200 mg

Capsules

Oral

Portugal

Laboratórios Pfizer, Lda.

Lagoas Park, Edifício n.o 10

P-2740-244 Porto Salvo

Celebrex

100 mg

Capsules

Oral

Laboratórios Pfizer, Lda.

Lagoas Park, Edifício n.o 10

P-2740-244 Porto Salvo

Celebrex

200 mg

Capsules

Oral

Lab. Medinfar — Produtos Farmacêuticos S.A.

R. Manuel Ribeiro de Pavia, n.o 1 — Venda Nova

P-2700-547 Amadora

Solexa

100 mg

Capsules

Oral

Lab. Medinfar — Produtos Farmacêuticos S.A.

R. Manuel Ribeiro de Pavia, n.o 1 — Venda Nova

P-2700-547 Amadora

Solexa

200 mg

Capsules

Oral

Slovenská republika

Pfizer Europe MA EEIG

Ramsgate Road

Sandwich

Kent CT13 9NJ

United Kingdom

Celebrex

100 mg

Capsules

Oral

Pfizer Europe MA EEIG

Ramsgate Road

Sandwich

Kent CT13 9NJ

United Kingdom

Celebrex

200 mg

Capsules

Oral

Slovenija

Pfizer Luxembourg SARL

283, route d'Arlon

L-8011 Strassen

Celebrex

100 mg

Capsules

Oral

Pfizer Luxembourg SARL

283, route d'Arlon

L-8011 Strassen

Celebrex

200 mg

Capsules

Oral

España

Pharmacia Spain S.A.

Avenida de Europa, 20-B

Parque Empresarial La Moraleja

E-28108 Alcobendas, Madrid

Celebrex

100 mg

Capsules

Oral

Pharmacia Spain S.A.

Avenida de Europa, 20-B

Parque Empresarial La Moraleja

E-28108 Alcobendas, Madrid

Artilog

100 mg

Capsules

Oral

Pharmacia Spain S.A.

Avenida de Europa, 20-B

Parque Empresarial La Moraleja

E-28108 Alcobendas, Madrid

Celebrex

200 mg

Capsules

Oral

Pharmacia Spain S.A.

Avenida de Europa, 20-B

Parque Empresarial La Moraleja

E-28108 Alcobendas, Madrid

Artilog

200 mg

Capsules

Oral

Sverige

Pfizer AB

Nytorpsvägen 36

P.O. Box 501

S-183 25 Täby

Celebra

100 mg

Capsules

Oral

Pfizer AB

Nytorpsvägen 36

P.O. Box 501

S-183 25 Täby

Celebra

200 mg

Capsules

Oral

Pfizer AB

Nytorpsvägen 36

P.O. Box 501

S-183 25 Täby

Solexa

100 mg

Capsules

Oral

Pfizer AB

Nytorpsvägen 36

P.O. Box 501

S-183 25 Täby

Solexa

200 mg

Capsules

Oral

Pfizer AB

Nytorpsvägen 36

P.O. Box 501

S-183 25 Täby

Celora

100 mg

Capsules

Oral

Pfizer AB

Nytorpsvägen 36

P.O. Box 501

S-183 25 Täby

Celora

200 mg

Capsules

Oral

Pfizer AB

Nytorpsvägen 36

P.O. Box 501

S-183 25 Täby

Aclarix

100 mg

Capsules

Oral

Pfizer AB

Nytorpsvägen 36

P.O. Box 501

S-183 25 Täby

Aclarix

200 mg

Capsules

Oral

Nederland

Pfizer bv

Rivium Westlaan 142

2909 LD Capelle a/d IJssel

Nederland

Celebrex

100 mg

Capsules

Oral

Pfizer bv

Rivium Westlaan 142

2909 LD Capelle a/d IJssel

Nederland

Celebrex

200 mg

Capsules

Oral

Pfizer bv

Rivium Westlaan 142

2909 LD Capelle a/d IJssel

Nederland

Solexa

100 mg

Capsules

Oral

Pfizer bv

Rivium Westlaan 142

2909 LD Capelle a/d IJssel

Nederland

Solexa

200 mg

Capsules

Oral

United Kingdom

Pfizer Ltd.

Ramsgate Road

Sandwich

Kent CT13 9NJ

United Kingdom

Celebrex

100 mg

Capsules

Oral

Pfizer Ltd.

Ramsgate Road

Sandwich

Kent CT13 9NJ

United Kingdom

Celebrex

200 mg

Capsules

Oral

Pfizer Ltd.

Ramsgate Road

Sandwich

Kent CT13 9NJ

United Kingdom

Solexa

100 mg

Capsules

Oral

Pfizer Ltd.

Ramsgate Road

Sandwich

Kent CT13 9NJ

United Kingdom

Solexa

200 mg

Capsules

Oral

---

ANNEX II

LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES AND NORWAY AND ICELAND

| Member State | Marketing Authorisation Holder | Invented name | Strength | Pharmaceutical Form | Route of administration |
| --- | --- | --- | --- | --- | --- |
| Belgique/België | Merck Sharp & Dohme BV
  Chaussée de Waterloo, 1135
  B-1180 Bruxelles | Arcoxia | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Chaussée de Waterloo, 1135
  B-1180 Bruxelles | Arcoxia | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Chaussée de Waterloo, 1135
  B-1180 Bruxelles | Arcoxia | 120 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Chaussée de Waterloo, 1135
  B-1180 Bruxelles | Ranacox | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Chaussée de Waterloo, 1135
  B-1180 Bruxelles | Ranacox | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Chaussée de Waterloo, 1135
  B-1180 Bruxelles | Ranacox | 120 mg | Film-coated tablet | Oral use |
| Κύπρος | Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Arcoxia | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Arcoxia | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Arcoxia | 120 mg | Film-coated tablet | Oral use |
| Danmark | Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Arcoxia | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Arcoxia | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Arcoxia | 120 mg | Film-coated tablet | Oral use |
| Deutschland | MSD Sharp & Dohme GmbH
  Lindenplatz 1
  D-85540 Haar | Etoricoxib MSD | 120 mg | Film-coated tablet | Oral use |
| MSD Sharp & Dohme GmbH
  Lindenplatz 1
  D-85540 Haar | Etoricoxib MSD | 90 mg | Film-coated tablet | Oral use |
| MSD Sharp & Dohme GmbH
  Lindenplatz 1
  D-85540 Haar | Etoricoxib MSD | 60 mg | Film-coated tablet | Oral use |
| MSD Sharp & Dohme GmbH
  Lindenplatz 1
  D-85540 Haar | Auxib | 120 mg | Film-coated tablet | Oral use |
| MSD Sharp & Dohme GmbH
  Lindenplatz 1
  D-85540 Haar | Auxib | 90 mg | Film-coated tablet | Oral use |
| MSD Sharp & Dohme GmbH
  Lindenplatz 1
  D-85540 Haar | Auxib | 60 mg | Film-coated tablet | Oral use |
| MSD Sharp & Dohme GmbH
  Lindenplatz 1
  D-85540 Haar | Arcoxia | 120 mg | Film-coated tablet | Oral use |
| MSD Sharp & Dohme GmbH
  Lindenplatz 1
  D-85540 Haar | Arcoxia | 90 mg | Film-coated tablet | Oral use |
| MSD Sharp & Dohme GmbH
  Lindenplatz 1
  D-85540 Haar | Arcoxia | 60 mg | Film-coated tablet | Oral use |
| Eesti | Merck Sharp & Dohme OÜ
  Peterburi tee 46
  EE-11415 Tallinn | Arcoxia | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme OÜ
  Peterburi tee 46
  EE-11415 Tallinn | Arcoxia | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme OÜ
  Peterburi tee 46
  EE-11415 Tallinn | Arcoxia | 120 mg | Film-coated tablet | Oral use |
| Suomi | Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Arcoxia | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Arcoxia | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Arcoxia | 120 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Turox | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Turox | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Turox | 120 mg | Film-coated tablet | Oral use |
| Ελλάδα | Vianex SA
  Tatoiou Street 18 Km
  Athens-Lamia National Road
  GR-14671 Nea Erythrea — Athene | Arcoxia | 60 mg | Film-coated tablet | Oral use |
| Vianex SA
  Tatoiou Street 18 Km
  Athens-Lamia National Road
  GR-14671 Nea Erythrea — Athene
  Griekenland | Arcoxia | 90 mg | Film-coated tablet | Oral use |
| Vianex SA
  Tatoiou Street 18 Km
  Athens-Lamia National Road
  GR-14671 Nea Erythrea — Athene | Arcoxia | 120 mg | Film-coated tablet | Oral use |
| Vianex SA
  Tatoiou Street 18 Km
  Athens-Lamia National Road
  GR-14671 Nea Erythrea — Athene | Turox | 60 mg | Film-coated tablet | Oral use |
| Vianex SA
  Tatoiou Street 18 Km
  Athens-Lamia National Road
  GR-14671 Nea Erythrea — Athene | Turox | 90 mg | Film-coated tablet | Oral use |
| Vianex SA
  Tatoiou Street 18 Km
  Athens-Lamia National Road
  GR-14671 Nea Erythrea — Athene | Turox | 120 mg | Film-coated tablet | Oral use |
| Magyarország | MSD Hungary Ltd.
  Alkotás utca 50
  H-1123 Budapest | Arcoxia | 60 mg | Film-coated tablet | Oral use |
| MSD Hungary Ltd.
  Alkotás utca 50
  H-1123 Budapest | Arcoxia | 90 mg | Film-coated tablet | Oral use |
| MSD Hungary Ltd.
  Alkotás utca 50
  H-1123 Budapest | Arcoxia | 120 mg | Film-coated tablet | Oral use |
| Ireland | Merck Sharp & Dohme Ltd
  Hertford Road
  Hoddesdon
  Hertfordshire EN11 9BU
  United Kingdom | Arcoxia | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme Ltd
  Hertford Road
  Hoddesdon
  Hertfordshire EN11 9BU
  United Kingdom | Arcoxia | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme Ltd
  Hertford Road
  Hoddesdon
  Hertfordshire EN11 9BU
  United Kingdom | Arcoxia | 120 mg | Film-coated tablet | Oral use |
| Island | Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Arcoxia | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Arcoxia | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Arcoxia | 120 mg | Film-coated tablet | Oral use |
| Italia | Merck Sharp & Dohme Italia SpA
  Via G. Fabbroni, 6
  I-00191 Roma | Arcoxia | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme Italia SpA
  Via G. Fabbroni, 6
  I-00191 Roma | Arcoxia | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme Italia SpA
  Via G. Fabbroni, 6
  I-00191 Roma | Arcoxia | 120 mg | Film-coated tablet | Oral use |
| Istituto Gentili SpA
  Via Benedetto Croce, 37
  I-56125 Pisa | Algix | 60 mg | Film-coated tablet | Oral use |
| Istituto Gentili SpA
  Via Benedetto Croce, 37
  I-56125 Pisa | Algix | 90 mg | Film-coated tablet | Oral use |
| Istituto Gentili SpA
  Via Benedetto Croce, 37
  I-56125 Pisa | Algix | 120 mg | Film-coated tablet | Oral use |
| Neopharmed SpA
  Via G. Fabbroni, 6
  I-00191 Roma | Recoxib | 60 mg | Film-coated tablet | Oral use |
| Neopharmed SpA
  Via G. Fabbroni, 6
  I-00191 Roma | Recoxib | 90 mg | Film-coated tablet | Oral use |
| Neopharmed SpA
  Via G. Fabbroni, 6
  I-00191 Roma | Recoxib | 120 mg | Film-coated tablet | Oral use |
| Addenda Pharma Srl
  Via dei Santi Pietro e Paolo, 30
  I-00144 Roma | Tauxib | 60 mg | Film-coated tablet | Oral use |
| Addenda Pharma Srl
  Via dei Santi Pietro e Paolo, 30
  I-00144 Roma | Tauxib | 90 mg | Film-coated tablet | Oral use |
| Addenda Pharma Srl
  Via dei Santi Pietro e Paolo, 30
  I-00144 Roma | Tauxib | 120 mg | Film-coated tablet | Oral use |
| Latvija | SIA ‘Merck Sharp & Dohme Latvija’
  Skanstes iela 13
  LV-1013 Riga | Arcoxia | 60 mg | Film-coated tablet | Oral use |
| SIA ‘Merck Sharp & Dohme Latvija’
  Skanstes iela 13
  LV-1013 Riga | Arcoxia | 90 mg | Film-coated tablet | Oral use |
| SIA ‘Merck Sharp & Dohme Latvija’
  Skanstes iela 13
  LV-1013 Riga | Arcoxia | 120 mg | Film-coated tablet | Oral use |
| Lietuva | Merck Sharp & Dohme UAB, Lithuania
  Gelezinio Vilko 18A
  LT-01112 Vilnius | Arcoxia | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme UAB, Lithuania
  Gelezinio Vilko 18A
  LT-01112 Vilnius | Arcoxia | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme UAB, Lithuania
  Gelezinio Vilko 18A
  LT-01112 Vilnius | Arcoxia | 120 mg | Film-coated tablet | Oral use |
| Luxembourg | Merck Sharp & Dohme SA
  Chaussée de Waterloo 1135
  B-1180 Bruxelles | Arcoxia | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme SA
  Chaussée de Waterloo 1135
  B-1180 Bruxelles | Arcoxia | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme SA
  Chaussée de Waterloo 1135
  B-1180 Bruxelles | Arcoxia | 120 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme SA
  Chaussée de Waterloo 1135
  B-1180 Bruxelles | Ranacox | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme SA
  Chaussée de Waterloo 1135
  B-1180 Bruxelles | Ranacox | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme SA
  Chaussée de Waterloo 1135
  B-1180 Bruxelles | Ranacox | 120 mg | Film-coated tablet | Oral use |
| Malta | Merck Sharp & Dohme Ltd
  Hertford Road
  Hoddesdon
  Hertfordshire EN11 9BU
  United Kingdom | Arcoxia | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme Ltd
  Hertford Road
  Hoddesdon
  Hertfordshire EN11 9BU
  United Kingdom | Arcoxia | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme Ltd
  Hertford Road
  Hoddesdon
  Hertfordshire EN11 9BU
  United Kingdom | Arcoxia | 120 mg | Film-coated tablet | Oral use |
| Nederland | Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Arcoxia | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Arcoxia | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Arcoxia | 120 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Auxib | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Auxib | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Auxib | 120 mg | Film-coated tablet | Oral use |
| Norge | Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Arcoxia | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Arcoxia | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Arcoxia | 120 mg | Film-coated tablet | Oral use |
| Österreich | Merck Sharp & Dohme GmbH
  Donau-City Straße 6
  A-1220 Wien | Arcoxia | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme GmbH
  Donau-City Straße 6
  A-1220 Wien | Arcoxia | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme GmbH
  Donau-City Straße 6
  A-1220 Wien | Arcoxia | 120 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme GmbH
  Donau-City Straße 6
  A-1220 Wien | Auxib | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme GmbH
  Donau-City Straße 6
  A-1220 Wien | Auxib | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme GmbH
  Donau-City Straße 6
  A-1220 Wien | Auxib | 120 mg | Film-coated tablet | Oral use |
| Polska | MSD Polska Sp. z.o.o.
  ul. Puławska 303
  PL-02-785 Warszawa | Arcoxia | 60 mg | Film-coated tablet | Oral use |
| MSD Polska Sp. z.o.o.
  ul. Puławska 303
  PL-02-785 Warszawa | Arcoxia | 90 mg | Film-coated tablet | Oral use |
| MSD Polska Sp. z.o.o.
  ul. Puławska 303
  PL-02-785 Warszawa | Arcoxia | 120 mg | Film-coated tablet | Oral use |
| Portugal | Merck Sharp & Dohme, Lda
  Quinta Da Fonte
  Edifício Vasco da Gama, n.o 19, Porto Salvo
  P-2770-192 Paço d'Arcos | Arcoxia | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme, Lda
  Quinta Da Fonte
  Edifício Vasco da Gama, n.o 19, Porto Salvo
  P-2770-192 Paço d'Arcos | Arcoxia | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme, Lda
  Quinta Da Fonte
  Edifício Vasco da Gama, n.o 19, Porto Salvo
  P-2770-192 Paço d'Arcos | Arcoxia | 120 mg | Film-coated tablet | Oral use |
| Laboratórios BIAL-Portela S.A.
  Av. Da Siderurgia Nacional
  P-4745-457 S. Mamede do Coronado | Exxiv | 60 mg | Film-coated tablet | Oral use |
| Laboratórios BIAL-Portela S.A.
  Av. Da Siderurgia Nacional
  P-4745-457 S. Mamede do Coronado | Exxiv | 90 mg | Film-coated tablet | Oral use |
| Laboratórios BIAL-Portela S.A.
  Av. Da Siderurgia Nacional
  P-4745-457 S. Mamede do Coronado | Exxiv | 120 mg | Film-coated tablet | Oral use |
| Farmacox-Companhia Farmacêutica, Lda.
  Quinta Da Fonte
  Edifício Vasco da Gama, n.o 19, Porto Salvo
  P-2770-192 Paço d'Arcos | Turox | 60 mg | Film-coated tablet | Oral use |
| Farmacox-Companhia Farmacêutica, Lda.
  Quinta Da Fonte
  Edifício Vasco da Gama, n.o 19, Porto Salvo
  P-2770-192 Paço d'Arcos | Turox | 90 mg | Film-coated tablet | Oral use |
| Farmacox-Companhia Farmacêutica, Lda.
  Quinta Da Fonte
  Edifício Vasco da Gama, n.o 19, Porto Salvo
  P-2770-192 Paço d'Arcos | Turox | 120 mg | Film-coated tablet | Oral use |
| Slovenija | Merck Sharp & Dohme Ltd.
  Šmartinska cesta 140
  SI-1000 Ljubljana | Arcoxia | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme Ltd.
  Šmartinska cesta 140
  SI-1000 Ljubljana | Arcoxia | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme Ltd.
  Šmartinska cesta 140
  SI-1000 Ljubljana | Arcoxia | 120 mg | Film-coated tablet | Oral use |
| Slovenská republika | Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Arcoxia | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Arcoxia | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Arcoxia | 120 mg | Film-coated tablet | Oral use |
| España | Merck Sharp & Dohme de España S.A.
  Josefa Valcárcel 38
  E-Madrid 28027 | Arcoxia | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme de España S.A.
  Josefa Valcárcel 38
  E-Madrid 28027 | Arcoxia | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme de España S.A.
  Josefa Valcárcel 38
  E-Madrid 28027 | Arcoxia | 120 mg | Film-coated tablet | Oral use |
| Laboratorios Abelló S.A.
  Josefa Valcárcel 38
  E-Madrid 28027 | Exxiv | 60 mg | Film-coated tablet | Oral use |
| Laboratorios Abelló S.A.
  Josefa Valcárcel 38
  E-Madrid 28027 | Exxiv | 90 mg | Film-coated tablet | Oral use |
| Laboratorios Abelló S.A.
  Josefa Valcárcel 38
  E-Madrid 28027 | Exxiv | 120 mg | Film-coated tablet | Oral use |
| Česká republika | Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Arcoxia | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Arcoxia | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Arcoxia | 120 mg | Film-coated tablet | Oral use |
| United Kingdom | Merck Sharp & Dohme Ltd
  Hertford Road
  Hoddesdon
  Hertfordshire EN11 9BU
  United Kingdom | Arcoxia | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme Ltd
  Hertford Road
  Hoddesdon
  Hertfordshire EN11 9BU
  United Kingdom | Arcoxia | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme Ltd
  Hertford Road
  Hoddesdon
  Hertfordshire EN11 9BU
  United Kingdom | Arcoxia | 120 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme Ltd
  Hertford Road
  Hoddesdon
  Hertfordshire EN11 9BU
  United Kingdom | Auxib | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme Ltd
  Hertford Road
  Hoddesdon
  Hertfordshire EN11 9BU
  United Kingdom | Auxib | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme Ltd
  Hertford Road
  Hoddesdon
  Hertfordshire EN11 9BU
  United Kingdom | Auxib | 120 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme Ltd
  Hertford Road
  Hoddesdon
  Hertfordshire EN11 9BU
  United Kingdom | Exxiv | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme Ltd
  Hertford Road
  Hoddesdon
  Hertfordshire EN11 9BU
  United Kingdom | Exxiv | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme Ltd
  Hertford Road
  Hoddesdon
  Hertfordshire EN11 9BU
  United Kingdom | Exxiv | 120 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme Ltd
  Hertford Road
  Hoddesdon
  Hertfordshire EN11 9BU
  United Kingdom | Turox | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme Ltd
  Hertford Road
  Hoddesdon
  Hertfordshire EN11 9BU
  United Kingdom | Turox | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme Ltd
  Hertford Road
  Hoddesdon
  Hertfordshire EN11 9BU
  United Kingdom | Turox | 120 mg | Film-coated tablet | Oral use |
| Sverige | Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Arcoxia | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Arcoxia | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Arcoxia | 120 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Turox | 60 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Turox | 90 mg | Film-coated tablet | Oral use |
| Merck Sharp & Dohme BV
  Waarderweg 39
  Postbus 581
  2003 PC Haarlem
  Nederland | Turox | 120 mg | Film-coated tablet | Oral use |

Member State

Marketing Authorisation Holder

Invented name

Strength

Pharmaceutical Form

Route of administration

Belgique/België

Merck Sharp & Dohme BV

Chaussée de Waterloo, 1135

B-1180 Bruxelles

Arcoxia

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Chaussée de Waterloo, 1135

B-1180 Bruxelles

Arcoxia

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Chaussée de Waterloo, 1135

B-1180 Bruxelles

Arcoxia

120 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Chaussée de Waterloo, 1135

B-1180 Bruxelles

Ranacox

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Chaussée de Waterloo, 1135

B-1180 Bruxelles

Ranacox

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Chaussée de Waterloo, 1135

B-1180 Bruxelles

Ranacox

120 mg

Film-coated tablet

Oral use

Κύπρος

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Arcoxia

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Arcoxia

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Arcoxia

120 mg

Film-coated tablet

Oral use

Danmark

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Arcoxia

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Arcoxia

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Arcoxia

120 mg

Film-coated tablet

Oral use

Deutschland

MSD Sharp & Dohme GmbH

Lindenplatz 1

D-85540 Haar

Etoricoxib MSD

120 mg

Film-coated tablet

Oral use

MSD Sharp & Dohme GmbH

Lindenplatz 1

D-85540 Haar

Etoricoxib MSD

90 mg

Film-coated tablet

Oral use

MSD Sharp & Dohme GmbH

Lindenplatz 1

D-85540 Haar

Etoricoxib MSD

60 mg

Film-coated tablet

Oral use

MSD Sharp & Dohme GmbH

Lindenplatz 1

D-85540 Haar

Auxib

120 mg

Film-coated tablet

Oral use

MSD Sharp & Dohme GmbH

Lindenplatz 1

D-85540 Haar

Auxib

90 mg

Film-coated tablet

Oral use

MSD Sharp & Dohme GmbH

Lindenplatz 1

D-85540 Haar

Auxib

60 mg

Film-coated tablet

Oral use

MSD Sharp & Dohme GmbH

Lindenplatz 1

D-85540 Haar

Arcoxia

120 mg

Film-coated tablet

Oral use

MSD Sharp & Dohme GmbH

Lindenplatz 1

D-85540 Haar

Arcoxia

90 mg

Film-coated tablet

Oral use

MSD Sharp & Dohme GmbH

Lindenplatz 1

D-85540 Haar

Arcoxia

60 mg

Film-coated tablet

Oral use

Eesti

Merck Sharp & Dohme OÜ

Peterburi tee 46

EE-11415 Tallinn

Arcoxia

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme OÜ

Peterburi tee 46

EE-11415 Tallinn

Arcoxia

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme OÜ

Peterburi tee 46

EE-11415 Tallinn

Arcoxia

120 mg

Film-coated tablet

Oral use

Suomi

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Arcoxia

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Arcoxia

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Arcoxia

120 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Turox

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Turox

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Turox

120 mg

Film-coated tablet

Oral use

Ελλάδα

Vianex SA

Tatoiou Street 18 Km

Athens-Lamia National Road

GR-14671 Nea Erythrea — Athene

Arcoxia

60 mg

Film-coated tablet

Oral use

Vianex SA

Tatoiou Street 18 Km

Athens-Lamia National Road

GR-14671 Nea Erythrea — Athene

Griekenland

Arcoxia

90 mg

Film-coated tablet

Oral use

Vianex SA

Tatoiou Street 18 Km

Athens-Lamia National Road

GR-14671 Nea Erythrea — Athene

Arcoxia

120 mg

Film-coated tablet

Oral use

Vianex SA

Tatoiou Street 18 Km

Athens-Lamia National Road

GR-14671 Nea Erythrea — Athene

Turox

60 mg

Film-coated tablet

Oral use

Vianex SA

Tatoiou Street 18 Km

Athens-Lamia National Road

GR-14671 Nea Erythrea — Athene

Turox

90 mg

Film-coated tablet

Oral use

Vianex SA

Tatoiou Street 18 Km

Athens-Lamia National Road

GR-14671 Nea Erythrea — Athene

Turox

120 mg

Film-coated tablet

Oral use

Magyarország

MSD Hungary Ltd.

Alkotás utca 50

H-1123 Budapest

Arcoxia

60 mg

Film-coated tablet

Oral use

MSD Hungary Ltd.

Alkotás utca 50

H-1123 Budapest

Arcoxia

90 mg

Film-coated tablet

Oral use

MSD Hungary Ltd.

Alkotás utca 50

H-1123 Budapest

Arcoxia

120 mg

Film-coated tablet

Oral use

Ireland

Merck Sharp & Dohme Ltd

Hertford Road

Hoddesdon

Hertfordshire EN11 9BU

United Kingdom

Arcoxia

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme Ltd

Hertford Road

Hoddesdon

Hertfordshire EN11 9BU

United Kingdom

Arcoxia

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme Ltd

Hertford Road

Hoddesdon

Hertfordshire EN11 9BU

United Kingdom

Arcoxia

120 mg

Film-coated tablet

Oral use

Island

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Arcoxia

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Arcoxia

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Arcoxia

120 mg

Film-coated tablet

Oral use

Italia

Merck Sharp & Dohme Italia SpA

Via G. Fabbroni, 6

I-00191 Roma

Arcoxia

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme Italia SpA

Via G. Fabbroni, 6

I-00191 Roma

Arcoxia

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme Italia SpA

Via G. Fabbroni, 6

I-00191 Roma

Arcoxia

120 mg

Film-coated tablet

Oral use

Istituto Gentili SpA

Via Benedetto Croce, 37

I-56125 Pisa

Algix

60 mg

Film-coated tablet

Oral use

Istituto Gentili SpA

Via Benedetto Croce, 37

I-56125 Pisa

Algix

90 mg

Film-coated tablet

Oral use

Istituto Gentili SpA

Via Benedetto Croce, 37

I-56125 Pisa

Algix

120 mg

Film-coated tablet

Oral use

Neopharmed SpA

Via G. Fabbroni, 6

I-00191 Roma

Recoxib

60 mg

Film-coated tablet

Oral use

Neopharmed SpA

Via G. Fabbroni, 6

I-00191 Roma

Recoxib

90 mg

Film-coated tablet

Oral use

Neopharmed SpA

Via G. Fabbroni, 6

I-00191 Roma

Recoxib

120 mg

Film-coated tablet

Oral use

Addenda Pharma Srl

Via dei Santi Pietro e Paolo, 30

I-00144 Roma

Tauxib

60 mg

Film-coated tablet

Oral use

Addenda Pharma Srl

Via dei Santi Pietro e Paolo, 30

I-00144 Roma

Tauxib

90 mg

Film-coated tablet

Oral use

Addenda Pharma Srl

Via dei Santi Pietro e Paolo, 30

I-00144 Roma

Tauxib

120 mg

Film-coated tablet

Oral use

Latvija

SIA ‘Merck Sharp & Dohme Latvija’

Skanstes iela 13

LV-1013 Riga

Arcoxia

60 mg

Film-coated tablet

Oral use

SIA ‘Merck Sharp & Dohme Latvija’

Skanstes iela 13

LV-1013 Riga

Arcoxia

90 mg

Film-coated tablet

Oral use

SIA ‘Merck Sharp & Dohme Latvija’

Skanstes iela 13

LV-1013 Riga

Arcoxia

120 mg

Film-coated tablet

Oral use

Lietuva

Merck Sharp & Dohme UAB, Lithuania

Gelezinio Vilko 18A

LT-01112 Vilnius

Arcoxia

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme UAB, Lithuania

Gelezinio Vilko 18A

LT-01112 Vilnius

Arcoxia

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme UAB, Lithuania

Gelezinio Vilko 18A

LT-01112 Vilnius

Arcoxia

120 mg

Film-coated tablet

Oral use

Luxembourg

Merck Sharp & Dohme SA

Chaussée de Waterloo 1135

B-1180 Bruxelles

Arcoxia

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme SA

Chaussée de Waterloo 1135

B-1180 Bruxelles

Arcoxia

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme SA

Chaussée de Waterloo 1135

B-1180 Bruxelles

Arcoxia

120 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme SA

Chaussée de Waterloo 1135

B-1180 Bruxelles

Ranacox

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme SA

Chaussée de Waterloo 1135

B-1180 Bruxelles

Ranacox

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme SA

Chaussée de Waterloo 1135

B-1180 Bruxelles

Ranacox

120 mg

Film-coated tablet

Oral use

Malta

Merck Sharp & Dohme Ltd

Hertford Road

Hoddesdon

Hertfordshire EN11 9BU

United Kingdom

Arcoxia

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme Ltd

Hertford Road

Hoddesdon

Hertfordshire EN11 9BU

United Kingdom

Arcoxia

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme Ltd

Hertford Road

Hoddesdon

Hertfordshire EN11 9BU

United Kingdom

Arcoxia

120 mg

Film-coated tablet

Oral use

Nederland

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Arcoxia

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Arcoxia

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Arcoxia

120 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Auxib

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Auxib

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Auxib

120 mg

Film-coated tablet

Oral use

Norge

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Arcoxia

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Arcoxia

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Arcoxia

120 mg

Film-coated tablet

Oral use

Österreich

Merck Sharp & Dohme GmbH

Donau-City Straße 6

A-1220 Wien

Arcoxia

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme GmbH

Donau-City Straße 6

A-1220 Wien

Arcoxia

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme GmbH

Donau-City Straße 6

A-1220 Wien

Arcoxia

120 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme GmbH

Donau-City Straße 6

A-1220 Wien

Auxib

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme GmbH

Donau-City Straße 6

A-1220 Wien

Auxib

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme GmbH

Donau-City Straße 6

A-1220 Wien

Auxib

120 mg

Film-coated tablet

Oral use

Polska

MSD Polska Sp. z.o.o.

ul. Puławska 303

PL-02-785 Warszawa

Arcoxia

60 mg

Film-coated tablet

Oral use

MSD Polska Sp. z.o.o.

ul. Puławska 303

PL-02-785 Warszawa

Arcoxia

90 mg

Film-coated tablet

Oral use

MSD Polska Sp. z.o.o.

ul. Puławska 303

PL-02-785 Warszawa

Arcoxia

120 mg

Film-coated tablet

Oral use

Portugal

Merck Sharp & Dohme, Lda

Quinta Da Fonte

Edifício Vasco da Gama, n.o 19, Porto Salvo

P-2770-192 Paço d'Arcos

Arcoxia

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme, Lda

Quinta Da Fonte

Edifício Vasco da Gama, n.o 19, Porto Salvo

P-2770-192 Paço d'Arcos

Arcoxia

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme, Lda

Quinta Da Fonte

Edifício Vasco da Gama, n.o 19, Porto Salvo

P-2770-192 Paço d'Arcos

Arcoxia

120 mg

Film-coated tablet

Oral use

Laboratórios BIAL-Portela S.A.

Av. Da Siderurgia Nacional

P-4745-457 S. Mamede do Coronado

Exxiv

60 mg

Film-coated tablet

Oral use

Laboratórios BIAL-Portela S.A.

Av. Da Siderurgia Nacional

P-4745-457 S. Mamede do Coronado

Exxiv

90 mg

Film-coated tablet

Oral use

Laboratórios BIAL-Portela S.A.

Av. Da Siderurgia Nacional

P-4745-457 S. Mamede do Coronado

Exxiv

120 mg

Film-coated tablet

Oral use

Farmacox-Companhia Farmacêutica, Lda.

Quinta Da Fonte

Edifício Vasco da Gama, n.o 19, Porto Salvo

P-2770-192 Paço d'Arcos

Turox

60 mg

Film-coated tablet

Oral use

Farmacox-Companhia Farmacêutica, Lda.

Quinta Da Fonte

Edifício Vasco da Gama, n.o 19, Porto Salvo

P-2770-192 Paço d'Arcos

Turox

90 mg

Film-coated tablet

Oral use

Farmacox-Companhia Farmacêutica, Lda.

Quinta Da Fonte

Edifício Vasco da Gama, n.o 19, Porto Salvo

P-2770-192 Paço d'Arcos

Turox

120 mg

Film-coated tablet

Oral use

Slovenija

Merck Sharp & Dohme Ltd.

Šmartinska cesta 140

SI-1000 Ljubljana

Arcoxia

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme Ltd.

Šmartinska cesta 140

SI-1000 Ljubljana

Arcoxia

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme Ltd.

Šmartinska cesta 140

SI-1000 Ljubljana

Arcoxia

120 mg

Film-coated tablet

Oral use

Slovenská republika

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Arcoxia

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Arcoxia

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Arcoxia

120 mg

Film-coated tablet

Oral use

España

Merck Sharp & Dohme de España S.A.

Josefa Valcárcel 38

E-Madrid 28027

Arcoxia

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme de España S.A.

Josefa Valcárcel 38

E-Madrid 28027

Arcoxia

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme de España S.A.

Josefa Valcárcel 38

E-Madrid 28027

Arcoxia

120 mg

Film-coated tablet

Oral use

Laboratorios Abelló S.A.

Josefa Valcárcel 38

E-Madrid 28027

Exxiv

60 mg

Film-coated tablet

Oral use

Laboratorios Abelló S.A.

Josefa Valcárcel 38

E-Madrid 28027

Exxiv

90 mg

Film-coated tablet

Oral use

Laboratorios Abelló S.A.

Josefa Valcárcel 38

E-Madrid 28027

Exxiv

120 mg

Film-coated tablet

Oral use

Česká republika

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Arcoxia

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Arcoxia

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Arcoxia

120 mg

Film-coated tablet

Oral use

United Kingdom

Merck Sharp & Dohme Ltd

Hertford Road

Hoddesdon

Hertfordshire EN11 9BU

United Kingdom

Arcoxia

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme Ltd

Hertford Road

Hoddesdon

Hertfordshire EN11 9BU

United Kingdom

Arcoxia

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme Ltd

Hertford Road

Hoddesdon

Hertfordshire EN11 9BU

United Kingdom

Arcoxia

120 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme Ltd

Hertford Road

Hoddesdon

Hertfordshire EN11 9BU

United Kingdom

Auxib

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme Ltd

Hertford Road

Hoddesdon

Hertfordshire EN11 9BU

United Kingdom

Auxib

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme Ltd

Hertford Road

Hoddesdon

Hertfordshire EN11 9BU

United Kingdom

Auxib

120 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme Ltd

Hertford Road

Hoddesdon

Hertfordshire EN11 9BU

United Kingdom

Exxiv

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme Ltd

Hertford Road

Hoddesdon

Hertfordshire EN11 9BU

United Kingdom

Exxiv

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme Ltd

Hertford Road

Hoddesdon

Hertfordshire EN11 9BU

United Kingdom

Exxiv

120 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme Ltd

Hertford Road

Hoddesdon

Hertfordshire EN11 9BU

United Kingdom

Turox

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme Ltd

Hertford Road

Hoddesdon

Hertfordshire EN11 9BU

United Kingdom

Turox

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme Ltd

Hertford Road

Hoddesdon

Hertfordshire EN11 9BU

United Kingdom

Turox

120 mg

Film-coated tablet

Oral use

Sverige

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Arcoxia

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Arcoxia

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Arcoxia

120 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Turox

60 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Turox

90 mg

Film-coated tablet

Oral use

Merck Sharp & Dohme BV

Waarderweg 39

Postbus 581

2003 PC Haarlem

Nederland

Turox

120 mg

Film-coated tablet

Oral use

---

ANNEX III

LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES AND NORWAY AND ICELAND

| Member State | Marketing Authorisation Holder | Invented name | Strength | Pharmaceutical Form | Route of administration |
| --- | --- | --- | --- | --- | --- |
| United Kingdom | Novartis Pharmaceuticals UK Ltd
  Frimley Business Park
  Frimley
  Camberley Surrey GU16 7SR
  United Kingdom | Prexige | 100 mg | Film-coated tablet | Oral |
| Novartis Pharmaceuticals UK Ltd
  Frimley Business Park
  Frimley
  Camberley Surrey GU16 7SR
  United Kingdom | Prexige | 200 mg | Film-coated tablet | Oral |
| Novartis Pharmaceuticals UK Ltd
  Frimley Business Park
  Frimley
  Camberley Surrey GU16 7SR
  United Kingdom | Prexige | 400 mg | Film-coated tablet | Oral |
| Novartis Pharmaceuticals UK Ltd
  Frimley Business Park
  Frimley
  Camberley Surrey GU16 7SR
  United Kingdom | Lumiracoxib | 100 mg | Film-coated tablet | Oral |
| Novartis Pharmaceuticals UK Ltd
  Frimley Business Park
  Frimley
  Camberley Surrey GU16 7SR
  United Kingdom | Lumiracoxib | 200 mg | Film-coated tablet | Oral |
| Novartis Pharmaceuticals UK Ltd
  Frimley Business Park
  Frimley
  Camberley Surrey GU16 7SR
  United Kingdom | Lumiracoxib | 400 mg | Film-coated tablet | Oral |
| Novartis Pharmaceuticals UK Ltd
  Frimley Business Park
  Frimley
  Camberley Surrey GU16 7SR
  United Kingdom | Frexocel | 100 mg | Film-coated tablet | Oral |
| Novartis Pharmaceuticals UK Ltd
  Frimley Business Park
  Frimley
  Camberley Surrey GU16 7SR
  United Kingdom | Frexocel | 200 mg | Film-coated tablet | Oral |
| Novartis Pharmaceuticals UK Ltd
  Frimley Business Park
  Frimley
  Camberley Surrey GU16 7SR
  United Kingdom | Frexocel | 400 mg | Film-coated tablet | Oral |
| Novartis Pharmaceuticals UK Ltd
  Frimley Business Park
  Frimley
  Camberley Surrey GU16 7SR
  United Kingdom | Stellige | 100 mg | Film-coated tablet | Oral |
| Novartis Pharmaceuticals UK Ltd
  Frimley Business Park
  Frimley
  Camberley Surrey GU16 7SR
  United Kingdom | Stellige | 200 mg | Film-coated tablet | Oral |
| Novartis Pharmaceuticals UK Ltd
  Frimley Business Park
  Frimley
  Camberley Surrey GU16 7SR
  United Kingdom | Stellige | 400 mg | Film-coated tablet | Oral |
| Novartis Pharmaceuticals UK Ltd
  Frimley Business Park
  Frimley
  Camberley Surrey GU16 7SR
  United Kingdom | Exforge | 100 mg | Film-coated tablet | Oral |
| Novartis Pharmaceuticals UK Ltd
  Frimley Business Park
  Frimley
  Camberley Surrey GU16 7SR
  United Kingdom | Exforge | 200 mg | Film-coated tablet | Oral |
| Novartis Pharmaceuticals UK Ltd
  Frimley Business Park
  Frimley
  Camberley Surrey GU16 7SR
  United Kingdom | Exforge | 400 mg | Film-coated tablet | Oral |

Member State

Marketing Authorisation Holder

Invented name

Strength

Pharmaceutical Form

Route of administration

United Kingdom

Novartis Pharmaceuticals UK Ltd

Frimley Business Park

Frimley

Camberley Surrey GU16 7SR

United Kingdom

Prexige

100 mg

Film-coated tablet

Oral

Novartis Pharmaceuticals UK Ltd

Frimley Business Park

Frimley

Camberley Surrey GU16 7SR

United Kingdom

Prexige

200 mg

Film-coated tablet

Oral

Novartis Pharmaceuticals UK Ltd

Frimley Business Park

Frimley

Camberley Surrey GU16 7SR

United Kingdom

Prexige

400 mg

Film-coated tablet

Oral

Novartis Pharmaceuticals UK Ltd

Frimley Business Park

Frimley

Camberley Surrey GU16 7SR

United Kingdom

Lumiracoxib

100 mg

Film-coated tablet

Oral

Novartis Pharmaceuticals UK Ltd

Frimley Business Park

Frimley

Camberley Surrey GU16 7SR

United Kingdom

Lumiracoxib

200 mg

Film-coated tablet

Oral

Novartis Pharmaceuticals UK Ltd

Frimley Business Park

Frimley

Camberley Surrey GU16 7SR

United Kingdom

Lumiracoxib

400 mg

Film-coated tablet

Oral

Novartis Pharmaceuticals UK Ltd

Frimley Business Park

Frimley

Camberley Surrey GU16 7SR

United Kingdom

Frexocel

100 mg

Film-coated tablet

Oral

Novartis Pharmaceuticals UK Ltd

Frimley Business Park

Frimley

Camberley Surrey GU16 7SR

United Kingdom

Frexocel

200 mg

Film-coated tablet

Oral

Novartis Pharmaceuticals UK Ltd

Frimley Business Park

Frimley

Camberley Surrey GU16 7SR

United Kingdom

Frexocel

400 mg

Film-coated tablet

Oral

Novartis Pharmaceuticals UK Ltd

Frimley Business Park

Frimley

Camberley Surrey GU16 7SR

United Kingdom

Stellige

100 mg

Film-coated tablet

Oral

Novartis Pharmaceuticals UK Ltd

Frimley Business Park

Frimley

Camberley Surrey GU16 7SR

United Kingdom

Stellige

200 mg

Film-coated tablet

Oral

Novartis Pharmaceuticals UK Ltd

Frimley Business Park

Frimley

Camberley Surrey GU16 7SR

United Kingdom

Stellige

400 mg

Film-coated tablet

Oral

Novartis Pharmaceuticals UK Ltd

Frimley Business Park

Frimley

Camberley Surrey GU16 7SR

United Kingdom

Exforge

100 mg

Film-coated tablet

Oral

Novartis Pharmaceuticals UK Ltd

Frimley Business Park

Frimley

Camberley Surrey GU16 7SR

United Kingdom

Exforge

200 mg

Film-coated tablet

Oral

Novartis Pharmaceuticals UK Ltd

Frimley Business Park

Frimley

Camberley Surrey GU16 7SR

United Kingdom

Exforge

400 mg

Film-coated tablet

Oral

---

| 30.12.2005 | EN | Official Journal of the European Union | C 334/58 |
| --- | --- | --- | --- |

30.12.2005

EN

Official Journal of the European Union

C 334/58

---

Summary of Community decisions on marketing authorizations in respect of medicinal products from 15 December 2004 to 15 January 2005

(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93 (1)

(2005/C 334/09)

—   Issuing of a marketing authorization (Article 12 of Council Regulation (EEC) No 2309/93): Accepted

| Date of the decision | Name of the medicinal product | Holder of the marketing authorization | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 12.1.2005 | Avastin | Roche Registration Limited |
| 40, Broadwater Road |
| Welwyn Garden City, Hertfordshire AL7 3AY |
| United Kingdom |

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

12.1.2005

Avastin

Roche Registration Limited

40, Broadwater Road

Welwyn Garden City, Hertfordshire AL7 3AY

United Kingdom

EU/1/04/300/001-002

14.1.2005

---

(1)   OJ L 214, 24.8.1993, p. 1.

---

| 30.12.2005 | EN | Official Journal of the European Union | C 334/59 |
| --- | --- | --- | --- |

30.12.2005

EN

Official Journal of the European Union

C 334/59

---

Publication of an application for registration pursuant to Article 6(2) of Regulation (EEC) No 2081/92 on the protection of geographical indications and designations of origin

(2005/C 334/10)

This publication confers the right to object to the application pursuant to Articles 7 and 12d of the abovementioned Regulation. Any objection to this application must be submitted via the competent authority in a Member State, in a WTO member country or in a third country recognized in accordance with Article 12(3) within a time limit of six months from the date of this publication. The arguments for publication are set out below, in particular under 4.6, and are considered to justify the application within the meaning of Regulation (EEC) No 2081/92

SUMMARY

COUNCIL REGULATION (EEC) No 2081/92

‘SANGUEIRA DE BARROSO — MONTALEGRE’

EC No: PT/00236/16.05.2002

PDO ( ) PGI ( X )

This summary has been drawn up for information purposes only. For full details, in particular the producers of the PDO or PGI concerned, please consult the complete version of the product specification obtainable at national level or from the European Commission (1).

1.   Responsible department in the Member State:

| Name: | Instituto de Desenvolvimento Rural e Hidráulica |
| --- | --- |
| Address: | Av. Afonso Costa, n.o 1949 — P-002 Lisboa |
| Tel.: | (351-21) 844 22 00 |
| Fax: | (351-21) 844 22 02 |
| Email: | idrha@idrha.min-agricultura.pt |

Name:

Instituto de Desenvolvimento Rural e Hidráulica

Address:

Av. Afonso Costa, n.o 1949 — P-002 Lisboa

Tel.:

(351-21) 844 22 00

Fax:

(351-21) 844 22 02

Email:

idrha@idrha.min-agricultura.pt

2.   Group:

2.1   Name: Cooperativa Agrícola dos Produtores de Batata para Semente de Montalegre, CRL

2.2   Address:

| Rua General Humberto Delgado 5470 — P-247 Montalegre, Portugal. |
| --- |
| Tel.: (351) 276 512 253 |
| Fax: (351) 276 512 528 |
| Email: quadrimonte@iol.pt |

Rua General Humberto Delgado 5470 — P-247 Montalegre, Portugal.

Tel.: (351) 276 512 253

Fax: (351) 276 512 528

Email: quadrimonte@iol.pt

2.3   Composition: producers/processors (X) other ( )

3.   Type of product:

Type 1.2 — Meat-based products

4.   Specification

(summary of requirements under Article 4(2)):

4.1   Name: ‘SANGUEIRA DE BARROSO — MONTALEGRE’

4.2   Description: A smoked sausage, made from the pig meat, pig fat and blood of the Bisaro breed or of cross-breeds that must be 50 % Bisaro, and wheat bread, made into a soft and dry paste in which small pieces of meat are visible, stuffed into a hog casing (small intestine). The ingredients are seasoned with salt, garlic, red or white wine from the Trás-os-Montes region, powdered chilli pepper (regionally known as ‘pimento’) and/or powdered red bell pepper (or ‘pimentão’), parsley, onion and olive oil from the Trás-os-Montes region. It is black in colour and has a rough exterior. It has a cylindrical section of approximately 3 cm in diameter. It is tied shut with two simple knots at each end, using a single piece of cotton twine, which gives the sausage a horseshoe shape.

4.3   Geographical area: Due to the special production requirements of these sausages, their flavours, the expertise available and the climatic conditions of the region, the geographical area for processing and packing is limited to the municipality of Montalegre, in the Vila Real district. Taking into account the traditional animal feed and existing agricultural production, the geographical area for processing and packing is naturally limited to the municipalities of Boticas, Chaves and Montalegre, in the Vila Real district. The territory consisting of these three municipalities is known and identified as ‘Barroso’.

4.4   Proof of origin: The farms, slaughterhouses and meat-cutting and preparation plants must be licensed, authorised by the group of producers after the private control body has given its approval, and located in the specified production or processing areas respectively. The entire production process, from the farm that produces the raw materials to the place where the product is sold, is subject to a rigorous control system ensuring the product is fully traceable. The pigs are reared in livestock farms possessing an area compatible with traditional, semi-extensive farming systems, where it is possible to produce traditional animal feed. The certification mark on each sausage is numbered, ensuring full traceability to the farm where the product originated. It is possible to prove the origin of the product at any point in the production chain by means of the serial number, which must be indicated on the certification mark.

4.5   Method of production: The fatty cuts of meat are cut into small pieces. The pig blood is drained and water is added, taking care to whisk the mixture to prevent coagulation. It is then seasoned with salt and garlic and left to rest. The wheat bread is cut into thin slices. The pig meat is seasoned with salt, red or white wine from the Trás-os-Montes region, and garlic. It is marinated for up to 3 days in a cool room with low humidity. The bread and blood are added to the meat mixture (regionally known as the sorsa), which is then seasoned with chilli pepper powder and/or red bell pepper powder, chopped parsley, chopped onion and raw olive oil. This mixture is then stuffed into a hog casing (small intestine). After stuffing, the casing is cut to the desired size after the ends have been knotted with cotton twine. The two ends are then tied with simple knots and the sausage is bent into a horseshoe shape. The sausage is smoked over a low fire in a smoking room or a traditional smokehouse for 3 to 4 days. The smoke is obtained through the direct combustion of wood, primarily oak, from the region. The sausage is placed on the market as a whole sausage and is always pre-packed at the place of origin. Due to the product's characteristics and composition, it cannot be cut or sliced. Special material, which is innocuous and inert when it comes into contact with the product, is used for its packaging. The product may be packed in a normal or controlled atmosphere or in a vacuum. Packing can only be carried out in the geographical processing area so as to ensure traceability and control and to prevent any change to the product's taste and microbiological characteristics.

4.6   Link: Due to climatic, geographic and socio–economic conditions, and the difficulty of communicating with the rest of the country, the diet of the Barroso region was limited to local products, mainly bread, potatoes and pork. References made to taxes on pigs and pork products in various municipal registers, including that of Montalegre, prove that pig-breeding has been important in this area for a very long time. For pork to remain edible throughout the year, ways were discovered to preserve it, and these quickly became ancestral skills passed down from one generation to the next. The preparation of these products is the result of, and is very dependent on, the region's cold and dry climate, which forces every household to keep a fire burning at all times, thus providing unique conditions for smoking, characterised by a light and gradual smoke supply. It was thus that the need to take advantage of and preserve the pig meat provided by the traditional slaughter gave rise to sausages of various shapes, different ingredients and different colours and flavours, but which were always an expression of the local characteristics: the land and its people. In short, the relationship between this product and the geographical area stems from the breed of (indigenous) animal, the local produce fed to these animals, the knowledge to choose the correct pieces of pig meat, the smoking process using regional firewood and the curing process conducted in a very cold and dry environment suitable for preserving the product.

4.7   Inspection body:

| Name: | Tradição e Qualidade — Associação Interprofissional para Produtos Agro-Alimentares de Trás-os-Montes |
| --- | --- |
| Address: | Av. 25 de Abril, 273 S/L P-5370 Mirandela |
| Tel.: | (351-278) 26 14 10 |
| Fax: | (351-278) 26 14 10 |
| Email: | tradicao-qualidade@clix.pt |

Name:

Tradição e Qualidade — Associação Interprofissional para Produtos Agro-Alimentares de Trás-os-Montes

Address:

Av. 25 de Abril, 273 S/L P-5370 Mirandela

Tel.:

(351-278) 26 14 10

Fax:

(351-278) 26 14 10

Email:

tradicao-qualidade@clix.pt

Tradição e Qualidade has been recognised as complying with the requirements of Standard 45011:2001.

4.8   Labelling: It is compulsory for the labelling to include the following: the wording ‘Sangueira de Barroso — Montalegre — Indicação Geográfica Protegida’ (Protected Geographical Indication), the Community's own logo, the logo for Barroso-Montalegre, reproduced below, together with the words ‘Montalegre’ and ‘Sangueira’. It must also include the certification mark, which must state the name of the product, the control body and the serial number (numeric or alphanumeric code ensuring the product's traceability).

4.9   National requirements: —

---

(1)  European Commission, Directorate-General for Agriculture, Agricultural product quality policy, B-1049 Brussels.

---

| 30.12.2005 | EN | Official Journal of the European Union | C 334/62 |
| --- | --- | --- | --- |

30.12.2005

EN

Official Journal of the European Union

C 334/62

---

Prior notification of a concentration

(Case COMP/M.4067 — Blackstone/Lion Capital/CSEB)

Candidate case for simplified procedure

(2005/C 334/11)

(Text with EEA relevance)

| 1. | On 20 December 2005, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertakings Blackstone Group (‘Blackstone’, USA) and Lion Capital General Partner LLP (‘Lion Capital’, UK) acquire within the meaning of Article 3(1)(b) of the Council Regulation control of the European Beverages Division of Cadbury Schweppes plc (‘CSEB’, France) by way of purchase of shares. |
| --- | --- |

1.

On 20 December 2005, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertakings Blackstone Group (‘Blackstone’, USA) and Lion Capital General Partner LLP (‘Lion Capital’, UK) acquire within the meaning of Article 3(1)(b) of the Council Regulation control of the European Beverages Division of Cadbury Schweppes plc (‘CSEB’, France) by way of purchase of shares.

| 2. | The business activities of the undertakings concerned are:






  — | for Blackstone: Private equity company; |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for Blackstone: Private equity company;

| — | for Lion Capital: Private equity company; |
| --- | --- |

—

for Lion Capital: Private equity company;

| — | for CSEB: Production, marketing and distribution of soft drinks. |
| --- | --- |

—

for CSEB: Production, marketing and distribution of soft drinks.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (No (32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4067 — Blackstone/Lion Capital/CSEB, to the following address:





  European Commission |
| --- | --- |
| Competition DG |
| Merger Registry |
| J-70 |
| B-1049 Brussels |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (No (32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4067 — Blackstone/Lion Capital/CSEB, to the following address:

European Commission

Competition DG

Merger Registry

J-70

B-1049 Brussels

---

(1)  OJ L 24, 29.1.2004, p. 1.

(2)  OJ C 56, 5.3.2005 p. 32.

---

European Defence Agency

| 30.12.2005 | EN | Official Journal of the European Union | C 334/63 |
| --- | --- | --- | --- |

30.12.2005

EN

Official Journal of the European Union

C 334/63

---

Communication relating to the revision of the financial provisions applicable to the general budget

(2005/C 334/12)

The Steering Board of the European Defence Agency has decided on 16 December 2005, to modify Title III (Procurement) of the financial provisions applicable to the general budget of the Agency (Annex to Decision 2004/658/PESC of the Council, of 13 September 2004, OJ L 300 of 25.9.2004, p. 52). The revised text is published in the following address:

http://www.eda.eu.int/procurement/procurement.htm

---